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Preface  
The studies for this thesis were made during my time as a PhD 
student at the Department of Cardiology, Aalborg University Hospi-
tal, from 2011 to 2014. The project was completed in collaboration 
with the Working Group on Arrhythmias and Device Therapy under 
the Danish Society of Cardiology, with data from five Danish ICD 
implanting centers in Aalborg, Aarhus, Odense, Gentofte, and 
Copenhagen. There are so many people to whom I owe my grati-
tude for their helpfulness, making this project possible: numerous 
research secretaries, ICD technicians, nurses, physicians, statisti-
cians, and industry technicians all over the country. I have been 
welcomed with open arms and have learned a great deal about this 
fascinating field of cardiology. With an honest heart I can say that 
our Danish national electrophysiological and device community 
indeed is a fantastic place to work bursting with smart, friendly, 
curious, innovative, and caring persons. Thank you all for your 
help. 
 I have been fortunate to have five clinical electrophysiologists 
as my academic advisors: Sam Riahi (main supervisor, Aalborg), 
Søren Pilkjær Hjortshøj (Aalborg), Anna Margrethe Thøgersen 
(Aalborg), Jens Cosedis Nielsen (Aarhus), and Jens Brock Johansen 
(Odense). It has been a blast working together with you on this 
project and getting to know you on a personal level. You have 
always given me sincere, honest, and constructive criticism and 
guidance on the project, but also left a room for my own ways: the 
ideal framework for a PhD study. I look forward to the continued 
collaboration across centers in the coming years.  
 In Aalborg, I would like to thank Consultant Ole Eschen and 
biostatisticians Søren Lundbye-Christensen, Martin Berg Johansen, 
and Karen Margrethe Due for valuable input to the project and 
statistical supervision; all the nurses in our ICD clinic for their valu-
able help with getting the project going; Professor Erik Berg 
Schmidt for letting me into his PhD student office and for input on 
scientific and practical questions despite my work being from an 
entirely different field within cardiology; all the researchers in our 
office for making a vibrant scientific environment and lots of fun in 
the last three years: Thomas, Michael, Jakob, Henrik, Vibeke, Stine, 
Anders, Steen, Christian, Line, Martin, and Anette; Research Secre-
tary Hanne Madsen for helping with so many things during my 
time as a PhD student.  
 Outside Aalborg, I would like to thank consultants Jens Haarbo 
(Gentofte), Regitze Videbæk (Rigshospitalet), and Helen Høgh 
Petersen (Rigshospitalet) for data collection and critical input to 
the studies; Data Manager Ole Dan Jørgensen and Nurse Lisbeth 
Skov Nielsen from the Danish Pacemaker and ICD Register (Oden-
se) for help with data extraction; Cardiology Fellow Rikke Kirkfelt 
Esbjerg (Aarhus) for sharing her experience working with device 
registry data; Associate Professor Dominic Theuns (the Nether-
lands) for valuable expert help in our first fluoroscopic screening; 
Professor Susanne Schmidt Pedersen (Odense) for introducing me 
to the important work of cardiac psychology using multi-item 
questionnaires. 
 The PhD project has only been possible due to financial support 
from the Danish Heart Foundation, the Danish Pacemaker and ICD 
Register, and the Department of Cardiology, Aalborg University 
Hospital. 
 Finally, I would like to thank my wonderful wife Sanne for her 
support and understanding and for taking care of our fantastic 
twins William and Sofia, often with a helping hand from our par-
ents, when I have been away from home.  
 
Jacob Moesgaard Larsen 
August 2014 
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Abbreviations  
 
CI    confidence interval 
EC    externalized conductor 
F    French gauge (1 F = 1/3 millimeter)  
FDA   American Food and Drug Administration 
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GAD-7   Generalized Anxiety Disorder questionnaire (7-item 
version) 
ICD   implantable cardioverter defibrillator 
ICDC-8   ICD patient Concerns questionnaire (8-item version) 
MAUDE  Manufacturers and User Facility Device Experience 
PHQ-9   Patient Health Questionnaire (9-item version) 
VAS   visual analog scale 
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Introduction 
The implantable cardioverter defibrillator (ICD) is the treatment of 
choice for the prevention of sudden cardiac death in high-risk 
patients.1, 2 As with any technology, the ICD has been associated 
with unexpected problems with several advisory notifications, also 
known as recalls, typically issued by the manufacturers according 
to the rules from the American Food and Drug Administration 
(FDA). The St. Jude Medical Riata defibrillator lead advisory was 
issued in November 2011 due to an increased risk of insulation 
defects including fluoroscopically visible externalized conductors 
(ECs) outside the protective silicone lead body.3 Initially, not much 
was known about the Riata lead failure mechanisms, and no clear 
association was seen between ECs and electrical function as most 
active leads were appearing to be well-functioning despite fluoro-
scopic status. These potentially failing Riata leads posed a major 
challenge to the worldwide device community with much uncer-
tainty, reviving unpleasant memories from the struggles with the 
preceding Medtronic Sprint Fidelis defibrillator lead advisory.4  
 Worldwide, at the time of the Riata advisory, 227,000 patients 
had received a recalled lead, and in the United States of America 
79,000 out of 141,000 leads were still active.3 In Denmark, 299 
patients had active Riata leads with an urgent need for manage-
ment. Our Riata investigations were started to help fill this 
knowledge gap by contributing with high quality data to enable the 
device community to provide the best care for our patients. This 
was managed on a national level in Denmark, and as recommend-
ed by the American Institute of Medicine, not only the technical 
characteristics of the advisory were investigated, but also patient-
centered aspects by including patient-reported outcomes (PROs) 
on general well-being and psychological function.5 The results of 
this joint national effort are presented in the studies in this thesis. 
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 Background 
The implantable cardioverter defibrillator 
Ventricular arrhythmia is the number one reason for out-of-
hospital cardiac arrest.6, 7 Out-of-hospital cardiac arrest has a poor 
prognosis and is a major cause of death.8 The concept of prevent-
ing sudden cardiac death using an implantable cardioverter defib-
rillator (ICD) was developed in the 1970s. In 1980, Mirowski et al 
performed the first human ICD implant.9 In the first years, the ICD 
technology was characterized by bulky simple devices (>200 g; 
>100 cc) with a low battery longevity <2 years requiring abdominal 
implant and thoracic surgery with epicardial patches to deliver 
sufficient defibrillation energy.10 Implants were associated with a 
high rate of complications and were only offered as secondary 
prevention in case of symptomatic ventricular arrhythmias. Mortal-
ity reduction compared with medical antiarrhythmic therapy was 
demonstrated in the pioneering randomized AVID, CIDS, and CASH 
studies.11-13 In a meta-analysis of these studies, the patients ran-
domized to ICD treatment had a relative risk of death of 72%, with 
an absolute risk reduction of 6.0% (mean follow-up 1.5 to 4.5 
years) giving a number needed to treat of 17.1 The benefit was less 
in patients with left ventricular ejection fraction >35%.  
 The ICD technology has been vastly improved, now featuring 
much smaller programmable devices (≈70 g; ≈35 cc) with longer 
battery longevity >6 years, higher energy output, more efficient 
biphasic shock waveform, active generator can, anti-tachycardia-
pacing, advanced brady-pacing capabilities, and intravascular leads 
with complete capability of sensing, pacing, and shock delivery.10 
An example of a modern transvenous ICD is depicted in Figure 1. 
The technical advances have simplified ICD implantation, making it 
similar to a standard pacemaker implant with pulse generator 
placement subcutaneously in the left pectoral area connected via a 
lead to the endocardial surface of the right ventricle through the 
central venous vasculature. ICD indications have expanded. Now, 
the majority of implants are primary prevention in patients with a 
high risk of sudden cardiac death, with demonstrated mortality 
reduction in several randomized trials, including MADIT, MUSTT, 
MADIT II, and ScD-HeFT.14-17 In a meta-analysis of 10 primary pre-
vention trials, the patients randomized to ICD treatment had a 
relative risk of death of 75% and an absolute risk reduction of 7.9% 
(mean follow-up 1.3 to 4.0 years) giving a number needed to treat 
of 13.2 Recently, an entirely subcutaneous ICD without intra-
vascular leads has been introduced for patients not dependent on 
pacing or cardiac synchronization therapy with promising prelimi-
nary outcomes.18, 19 
Figure 1 
 
Modern transvenous implantable cardioverter defibrillator. Left: A pulse 
generator in a titanium box (66 x 51 x 12 mm; 67 g; 30 cc). Right: A dual coil 
defibrillator lead with active fixation (8-F = 2.7 mm diameter and length 52-
65 cm). The pulse generator is placed subcutaneously in the left pectoral 
area and connected via the intravascular lead to the right ventricle. Courte-
sy of St. Jude Medical. 
 
Figure 2 
 
First implants of implantable cardioverter defibrillators (ICD) in Denmark 
from 2000 to 2013. Data reproduced with permission from the Danish ICD 
Register, June 2014. 
 
ICD implantation in Denmark and the Danish 
Pacemaker and ICD Register 
In Denmark, the first ICD implantation was performed in 1989 in 
Aarhus. The implant rate has increased, especially since 2007, with 
the introduction of primary prevention mainly in patients with 
symptomatic heart failure and concomitant ischemic heart disease 
(Figure 2). In 2013, the rate of first ICD implants was 212 per mil-
lion inhabitants and seems to have reached a plateau. All Danish 
ICD implants have been performed at five university hospitals, and 
from 2013 also one non-university hospital. 
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 Since 1982, the Danish Pacemaker and ICD Register has collect-
ed data from all cardiac implantable electronic device implants and 
subsequent surgical system interventions.20 The implanting physi-
cians report hardware specifications, procedure-related data, and 
selected clinical characteristics. After discharge, the patients are 
followed in outpatient clinics with regular visits and, if possible, 
supplementary remote monitoring. The number of variables re-
ported increased in 2007. Data on ICD therapy, complications, and 
anti-arrhythmic medical therapy are reported by the technicians in 
the outpatient clinics.  
  
Defibrillator lead design  
The evolution of defibrillator leads is a success story with a steady 
development toward smaller and more reliable leads, but with a 
few backward steps along the way. The early intra-vascular defibril-
lator lead designs were coaxial with an inner central conductor 
surrounded by a tubular insulation, a tubular conducting shield, 
and an outer protecting jacket with large diameters of up to 14-F (F 
= French gauge =  1/3 mm → 14-F = 4.7 mm). Modern defibrillator 
leads have very complex multi-lumen designs with diameters <9-F, 
consisting of more than 40 separate parts of various materials. The 
low and high voltage conductors are protected by layers of insula-
tion consisting of a mixture of materials with different strengths 
and limitations: silicone (biocompatible, biostable, flexible but 
soft), polyurethane (biocompatible and stiff but prone to stress 
fracture and metal ion oxidation), and fluoropolymers (very bio-
compatible and stiff but prone to micro insulation failures).10 Shock 
coils in the newest lead generations are coated with expanded 
fluoropolymers or backfilling with medical adhesive and flat-wire 
design to reduce tissue in-growth, which eases lead extraction, for 
example in case of infection or lead dysfunction. Due to common 
industry standards, defibrillator leads from one manufacturer can 
be used with pulse generators from competing manufacturers 
using either the classic DF-1/IS-1 connectors (pace-sense cables 
and defibrillation cables from each shock coil are connected sepa-
rately) or the newer DF-4 connector (all cables combined in one 
single connection). 
 
Defibrillator lead failure 
The defibrillator lead is the Achilles heel of the ICD system. Even 
modern lead designs have relatively high rates of electrical failure, 
most often due to insulation defects with estimated overall 5-year 
and 10-year failure-free survival of <85-90% and <60-75%, respec-
tively.21, 22 However, if death as a competing risk is accounted for, 
the cumulative incidence of lead failure at 5 years has been re-
ported to be only 2.5% of the implanted leads.23 Failure rates in 
different studies are not easily compared as criteria for failure 
usually vary.24 The key problem is that the current monitoring of 
lead integrity is limited as stable measurements of, for example, 
pacing impedance can be within normal limits despite clinically 
important insulation failures or conductor fractures.25 Therefore, 
clinical expert evaluations are often needed to diagnose lead fail-
ure, and this judgment will vary depending on experience and 
aggressiveness in resorting to lead replacement in case of subtle 
electrical changes. The clinical presentation of defibrillator lead 
failure is variable from subclinical changes in electrical measure-
ments (pacing threshold, R-wave sensing, and impedances) to 
clinical therapy failure or painful inappropriate shock therapy due 
to noise. The risk of ICD malfunctions has decreased with hardware 
improvements, but is still a significant but accepted drawback of 
ICD treatment due to the high mortality reduction with low num-
bers needed to treat in primary and secondary prevention.1, 2 
 
Class I advisory notifications – unexpected 
serious hardware malfunctions 
ICD hardware malfunctions that emerge after market introduction 
are communicated by the manufacturers in accordance with the 
rules from the FDA.26, 27 These communications of device problems 
have for several years been recommended by the American Heart 
Rhythm Society to be called “advisory notifications” or “safety 
warnings”. These terms are more neutral than “device recall” 
which may mislead the physicians and patients to believe that the 
communication is synonymous to an unavoidable need for device 
removal. However, the FDA and most researchers still use these 
terms interchangeably. The most serious communication is a class I 
advisory issued in case of a reasonable probability that the use of 
the product will cause serious adverse health consequences or 
death. In the last decade, two major class I advisories concerning 
small-diameter defibrillator leads have been issued, i.e. the Med-
tronic Sprint Fidelis lead family due to conductor fractures and the 
St. Jude Medical Riata lead family due to insulation failures.3, 4 
These recalled lead families are clearly outperformed by larger-
diameter benchmark leads such as Sprint Quattro (Medtronic) and 
Endotak Reliance (Boston Scientific).28 They were approved for 
clinical use via the fast FDA 510k-pathway without any demands 
for clinical testing, as they were considered improved updates of 
existing leads. Worldwide, both lead families reached more than 
200,000 implants before the advisory notifications were issued. 
The fast 510k-pathway for approval has been demonstrated to be 
significantly overrepresented compared with the more compre-
hensive and slower pre-market approval-pathway in recalled cardi-
ac implantable electronic devices.29   
 The impact of advisory notifications on health-related quality of 
life, including psychological functioning, is unsettled. It has been 
investigated in relation to the Sprint Fidelis lead advisory with 
conflicting results, but these studies are limited by the fact that 
they were performed a long time (9-24 months) after the patients 
were exposed to the advisory.30-33 Research on the patient-
centered aspects of advisory notifications is needed as pointed out 
in a recent scientific statement endorsed by the Heart Rhythm 
Society.34  
 
Extraction of non-functional or potentially failing 
leads 
When a defibrillator lead fails, it has to be replaced, preferably 
before inappropriate shock therapy or therapy failure. The timing 
in management of the non-functional or potentially failing recalled 
lead is challenging, and the choice between abandonment, extrac-
tion, or adding a supplementary pace-sense or shock-lead is not 
always easy. The decision should be based on an individual risk-
benefit evaluation. Extraction of non-functional or recalled leads 
without concurrent infection and no immediate threat to the pa-
tient is a class IIa or IIb recommendation depending on the per-
ceived threat of the lead to the patient with level of evidence C 
(expert opinion).35  
 In a recent review of the hastily increasing extraction literature, 
most studies show high procedural success rates >95% with a low 
mean rate of major complications of 1.8% and mortality of 0.4%.36 
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 Defibrillator leads can usually be explanted by simple traction 
within the first 12 months after implant, but thereafter it is often a 
much more complicated procedure due to fibrous adhesions to 
other leads, endocardial structures, and venous vasculature with 
need for mechanical or laser-powered large diameter sheaths, with 
outcomes highly dependent on operator experience. The typical 
minor complication is pocket hematoma, and the most feared 
major complications are perforation of the heart and central vascu-
lature with tamponade or hemothorax with a high risk of fatal 
outcome despite acute thoracotomy.37, 38 Dual coil leads are more 
difficult and dangerous to remove due to the position of the prox-
imal shock coil at the vulnerable level of the superior vena cava, 
especially if the shock coils are not backfilled or coated with ex-
panded fluoropolymers.39 A European survey highlights a concern-
ing fact that despite the known importance of operator experience 
for outcomes, most extractions in real life are performed in centers 
with high implant rates but low extraction rates with variable 
backup from thoracic surgeons.40 The outcomes of lead extraction 
under these real life circumstances outside the large high-volume 
extraction centers are not known. However, in two small single 
center studies the proportions of major complications were as high 
as 4.2% and 7.6%, respectively.41, 42  
 
The recalled St. Jude Medical Riata leads 
investigated in the present thesis 
The Riata 8-F leads introduced to the market in 2002 and their 
successors, the Riata ST 7-F leads released in 2005, were recalled in 
November 2011 due to a high rate of insulation defects, including 
inside-out movement of conductor cables outside the protective 
silicone body known as externalization or externalized conductors 
(ECs).43 Externalization can increase the risk of erosion of the eth-
ylene-tetrafluroethylene insulation of the conductor cables, but 
most leads in the first systematic fluoroscopic screening from 
Northern Ireland appeared to have normal electrical function 
despite fluoroscopically visible ECs.43 A total of 20 sub-models 
were recalled (8-F models: 1560, 1561, 1562, 1570, 1571, 1572, 
1580, 1581, 1582, 1590, 1591, and 1592; 7-F models: 7000, 7001, 
7002, 7010, 7011, 7040, 7041, and 7042). The Riata ST Optim leads 
introduced in 2006 have not been recalled due to the addition of 
an outer protective jacket of a durable silicone-polyurethane co-
polymer (Optim), which is 50 times stronger than silicone and 
thereby significantly reduces the risk of inside-out and outside-in 
insulation defects. 
 The recalled Riata leads are good examples of modern multi-
lumen defibrillator lead designs (Figure 3). The lead body is com-
posed of silicone with a polytetrafluoroethylene covered pace-
sense coil to the lead tip electrode in the center surrounded by two 
(in single coil lead) or three (in dual coil lead) oversized lumens 
with separate pairs of ethylene-tetrafluoroethylene covered low-
voltage or high-voltage conductor cables to distal ring, distal shock 
coil, and proximal shock coil, respectively. In ten of the recalled 
sub-models with integrated bipolar sensing (no ring electrode), 
identical but passive pairs of filler conductor cables are placed in 
the lumen to keep a balanced design.44 These passive filler cables 
are only attached distally by silicone adhesive instead of mechani-
cal crimps as for active cables. Comparing the 7-F lead with the 8-F 
predecessor, the main differences are smaller lead diameter with 
conductor cables closer to the lead center, reducing the shear 
stress of lead bending exerted by the constant movement of the 
myocardium and improved shock coil design with flat-wire and 
silicone backfilling. 
 The development of ECs has been suggested to be caused by 
the combination of a flexible silicone lead body fixed to the central 
venous vasculature by fibrosis and the free moving much stiffer 
internal conductors in the oversized lumens, which enables differ-
ential lead component pulling by movement of the myocardium 
and skeletal muscles, so that the conductor cables can saw their 
way inside-out through the soft silicone.45  
 
Figure 3 
 
Schematic outline of main design element in an 8-F recalled Riata lead with dual coil and passive fixation. Left: Truncated view of the lead from connector to 
tip. Right: Cross-section of lead body proximal to the superior vena cava shock coil. ETFE = Ethylene-tetrafluoroethylene; PTFE = polytetetrafluoroethylene. 
Courtesy of St. Jude Medical. 
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Aims and hypotheses 
The overall aim of the studies in this thesis was to provide data to 
support an evidence-based clinical management of ICD patients 
living under the Riata defibrillator lead class I advisory. The specific 
aims and hypotheses addressed in the three studies are presented 
below.  
 
Study I  
Aims: To determine the prevalence of ECs in a nationwide screen-
ing of active recalled Riata leads, and secondarily to examine time 
dependence and location of ECs, association with electrical abnor-
malities, fluoroscopic diagnostic performance, and potential pre-
dictors of ECs. 
 Primary hypothesis: The prevalence of ECs in a nationwide 
screening is relatively high but may be lower than reported in 
singlecenter studies due to minimal patient selection. 
 Secondary hypotheses: (1) The degree of externalization is 
associated with lead dwell time. (2) The most common location of 
ECs is intracardiac due to a high level of mechanical stress. (3) ECs 
are associated to electrical abnormalities. (4) The clinical diagnostic 
properties of fluoroscopy for detection of ECs are acceptable. (5) 
The rate of ECs is dependent on lead diameter and number of 
shock coils (exploratory analysis). 
 
Study II 
Aims: To describe the longitudinal dynamic nature of ECs and to 
investigate the clinical impact of ECs on electrical function and lead 
extraction outcomes. 
 Primary hypothesis: The evolution of ECs is dynamic with pro-
gression in size and new incident events over time. 
 Secondary hypotheses: (1) The incidence rate of electrical 
abnormalities in recalled Riata leads is relatively high, especially in 
patients with baseline ECs. (2) Lead extraction outcomes are good 
with a high rate of success and a low rate of complications. Lead 
extraction as compared with abandonment will be more frequent 
in younger patients in case of lead replacement. (3) The typical 
location of new ECs is in the intracardiac location and more fre-
quently near the distal coil in dual-coil models. 
 
Study III 
Aims: To describe the acute impact of the Riata advisory on pa-
tients’ well-being and psychological functioning and changes over 
time. 
 Primary hypothesis: In the early phase of the advisory, patients 
with recalled Riata leads will report poorer psychological function-
ing, especially seen in disease-specific measures of device-
acceptance and device-related concerns compared with non-
advisory controls. 
 Secondary hypotheses:  (1) Patients with recalled Riata leads 
are expected to adapt to the advisory notification during 1-year 
follow-up, with improvements seen especially in disease-specific 
measures of device-acceptance and device-related concerns. (2) 
Younger age, female sex, baseline ECs, and Type D personality are 
expected to be predictors of an acute high impact of the advisory 
on general well-being. 
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 Methods
Detailed descriptions of methods are given in each paper. Here is a 
shorter description with additional information on methodological 
considerations including explanations for differences in measures 
in Study I and Study II as a result of the hastily increasing 
knowledge on the Riata lead advisory over time. 
 
Data from the Danish Pacemaker  
and ICD Register  
In 2013, I made an unpublished internal audit by means of chart 
review of a random sample of 200 first-time ICD implants from 
2007 to 2012 including all ICD centers. This audit showed accepta-
ble positive predictive values for defibrillator lead model (95.3%), 
pulse generator model (96.5%), and implant diagnosis (91.6%). 
 
The Riata study cohort and design of 
the three studies 
From 2003 to 2010, a total of 486 patients had an implant with a 
recalled 8-F or 7-F Riata defibrillator lead at five university hospi-
tals in Denmark. In March 2012, a survivor cohort of all living 299 
Danish patients with active recalled Riata leads were identified in 
the Danish Pacemaker and ICD Register. The patients underwent a 
2012 baseline fluoroscopic and electrical screening with one year 
of follow-up including a second similar 2013 screening. In connec-
tion with these screenings, sets of questionnaires with PROs were 
completed by the patients tapping into their well-being and psy-
chological functioning.  
 Study I (n = 298): was a prospective cross-sectional study on the 
Riata cohort reporting on the baseline fluoroscopic and electrical 
screening. Primary endpoint was prevalent ECs. Secondary end-
points were location of ECs, degree of externalization, and preva-
lent electrical abnormalities.   
 Study II (n = 295): was a prospective longitudinal study on the 
Riata cohort reporting on fluoroscopic and electrical follow-up 
from baseline to the second screening. Primary endpoint was 
incident ECs. Secondary endpoints were incident electrical abnor-
malities, change in length of ECs, location of incident ECs, extrac-
tion outcomes, and prevalent ECs and electrical abnormalities in 
active leads at the second screening. 
 Study III (n = 256 x 2 = 512): was a prospective longitudinal 
study on the Riata cohort reporting on PROs at baseline and at 
follow-up, with a cross-sectional baseline comparison with a con-
temporary sample of non-advisory controls matched 1:1 by ran-
dom on age (5-year groups), sex, and implant indication (primary 
vs. secondary). Non-advisory patients enrolled in the DEFIB-
WOMEN Study with response to a set of questionnaires 12 months 
after ICD implant were eligible for matching. The DEFIB-WOMEN 
Study is an ongoing Danish prospective observational study on 
consecutive patients with a first-time ICD implant designed to 
evaluate gender differences in PROs and clinical outcomes. Primary 
endpoints in Study III were measures of device acceptance and 
device-related concerns. Secondary endpoints were generic 
measures of symptoms of depression and anxiety, and a purpose-
designed question on the impact of the advisory on general well-
being.     
 
Fluoroscopy and definitions of ECs (Study I & II)  
At the two fluoroscopic screenings, the Riata leads were examined 
in full length with cine-loops in three projections at a recommend-
ed frame rate of 15 per second: posterior-anterior, left anterior 
oblique 45° or best possible, and right anterior oblique 45° or best 
possible. Fluoroscopy was repeated in case of lead discontinuation 
before the second screening.    
 When the baseline screening was started early 2012, no guide-
lines for evaluation of ECs were available, and therefore we adjudi-
cated the presence and extent of ECs in collaboration with Dr. 
Theuns from the Erasmus Medical Center in the Netherlands, who, 
at that time, was finishing the largest fluoroscopic screening study 
to date with more than 1000 Riata leads.46 From the Dutch cohort, 
we adapted the use of the following criteria in the evaluation of 
ECs: the main criterion for ECs was a distance perpendicular across 
the conductors larger than the width of the lead body. Additional 
signs were a different radius of curvature of the conductors and an 
independent pattern of movement during the cine-loops of the 
conductors compared with the rest of the lead body.  
 In Study I, we conservatively considered only leads with a clear 
separation of the conductors from the lead body as having ECs. 
Leads with visible localized abnormal spacing between conductors 
just at the limit of the lead body width and a slightly abnormal 
radius of curvature of the conductors compared with the rest of 
the lead body were categorized as “abnormal conductor spacing”. 
In Study II, we included the leads previously classified as “abnor-
mal conductor spacing” in the definition of ECs and named it “bor-
derline EC”. This change to analyze all leads with abnormal fluoros-
copies as a common entity seemed appropriate as in the mean-
time, St. Jude Medical had issued guidelines on the evaluation of 
ECs that included a different radius of curvature of the suspected 
EC as a valid criterion for EC despite no visible separation of con-
ductors from the lead body.47 Figure 4 shows examples of leads 
with (i) no EC, (ii) abnormal conductor spacing / borderline EC, and 
(iii) overt EC. In both studies, the fluoroscopic diagnosis of ECs was 
adjudicated using centralized re-evaluation of all fluoroscopies 
involving multiple investigators. 
 EC location was categorized into three zones: distal, intermedi-
ate, and proximal (Figure 5). 
 In Study I, the size of ECs was described by four degrees: (1) 
localized abnormal conductor spacing without overt externaliza-
tion; (2) externalization <1 cm length; (3) externalization >1 cm 
length in one zone; and (4) externalization >1 cm length crossing 
adjacent zones. As mentioned, localized abnormal conductor spac-
ing was not considered an EC but was included in the scale as it 
was considered to precede the development of overt EC. In Study 
II, a more refined evaluation of EC size was performed by meas-
urement on fluoroscopic still pictures of the maximal linear length 
of the conductors from lead body exit to entry. The diameter of the 
distal coil was used as scale to adjust for magnification (Figure 6) 
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Figure 4 
Examples of fluoroscopic still pictures of recalled Riata leads. Left: Normal lead without any signs of externalized conductors; Middle: Abnormal conductor 
spacing (Study I) or borderline externalized conductors (Study II) with no clear separation of the suspected conductor from the silicone lead body. There is, 
however, an abnormal localized conductor spacing (arrow), which is most evident during cine-loops rather than still pictures with a slight difference in the 
radius of curvature between conductors. Right: Large defect with overt externalized conductors (arrow).  Abnormal conductor spacing (ACS) is equivalent to 
borderline externalized conductor (EC). 
 
Figure 5 
 
Location of externalization divided into three zones (1) Distal - below 
tricuspid valve annulus; (2) Intermediate - from tricuspid valve annulus up 
to superior vena cava (single coil leads) or proximal coil (dual coil leads); (3) 
Proximal - superior vena cava (single coil leads) or proximal coil (dual coil 
leads) and above. 
 
Figure 6 
 
Single coil Riata lead with overt externalization (marked by blue arrows). 
The length of the externalized conductors outside the lead body was meas-
ured (dotted white arrow), and distal coil was used as scale to adjust for 
differences in magnification (solid white arrows).  
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 Device interrogation and definitions of  
electrical abnormalities (Study I & II) 
Device interrogation was performed with standard clinical pro-
grammers from several manufacturers with measurements of 
pacing threshold, R-wave sensing, pacing impedance, and inspec-
tion of electrograms for non-physiological noise. High voltage lead 
impedance testing was only encouraged if painless integrity check 
was available, as this test seemed to be of limited value to predict 
high voltage short circuits. Prior to our Study I, Dr. Theuns had 
experienced a case at his Dutch hospital with a Riata lead short 
circuit at high voltage shock testing despite normal values at low 
voltage testing of the shock impedance.   
 In Study I, prevalent electrical abnormalities were defined by 
absolute limits and relative changes since latest follow-up: pacing 
threshold >5V or >100% increase; R-wave sensing <3.0mV or >50% 
reduction; pacing impedance outside the interval 200-2000 Ω or 
>100% increase or >50% decrease; high voltage lead impedance 
outside the interval 20-200 Ω or >100% increase or >50% decrease; 
electrogram with non-physiological noise; and previous lead failure 
with implant of supplementary leads. This definition was based on 
a mutual agreement between the investigators from the Danish 
centers inspired by the definitions used in the early Riata studies 
without fluoroscopies and the ongoing fluoroscopic Riata study in 
the Netherlands run by Dr. Theuns.46, 48-50  
 In Study II, incident electrical abnormalities were evaluated in 
patients with normal electrical function at the baseline screening. 
Due to the longitudinal design, incident electrical abnormalities 
were defined as a composite of three: (1) lead discontinuation due 
to a new electrical abnormality adjudicated by a panel of three 
electrophysiologists with access to data on electrical function from 
baseline to discontinuation but blinded from fluoroscopic status, 
(2) death due to a new electrical abnormality evaluated by review-
ing available data in medical records; and (3) new electrical ab-
normalities at device interrogation at the second screening with 
values outside absolute limits or relative changes since the base-
line screening (criteria as at baseline). 
 
Questionnaires for evaluation of PROs (Study III) 
In connection with the nationwide screenings, a set of standard-
ized and validated multi-item questionnaires and purpose-
designed questions were completed to measure PROs. The Type D 
personality measure was included to strengthen adjustment for 
potential confounding in statistical analyses. The matched non-
advisory controls did not complete the generic questionnaire on 
general anxiety. 
 Device acceptance: was evaluated using the 12-item Florida 
Patient Acceptance Survey (FPAS-12). Two separate studies with 
Danish and Dutch ICD patients indicate that the FPAS might be 
better used as a 12-item version than the original 18-item ver-
sion.51, 52 Examples of items are “Thinking about the device makes 
me depressed” and “The positive benefits of this device outweigh 
the negatives”. All items are rated on a 5-point Likert scale from 1 
(strongly disagree) to 5 (strongly agree). The total score was calcu-
lated and linearly converted into a score from 0 to 100, with a 
higher score indicating better device acceptance. The internal 
consistency was good with Cronbach’s alpha of 0.79 and similar to 
that found in a previous study of 0.82.52 A high Chronbach’s alpha 
represents a high mean inter-correlation between the items in a 
questionnaire and therefore indirectly describes the degree to 
which a set of items measures a single latent construct, i.e. a com-
plex psychological variable such as device acceptance.53 A well-
accepted guideline for acceptable values of Chronbach’s alpha is 
0.70 to 0.90. 
 Device-related concerns: were evaluated using the 8-item ICD 
patient Concerns questionnaire (ICDC-8).54 Example of an item is “I 
am worried about my ICD firing”. All items are rated on a 5-point 
Likert scale from 0 (not at all) to 4 (very much so). The total score 
ranges from 0 to 32, with a higher score indicating increased de-
vice-related concerns. The internal consistency was excellent, with 
Cronbach’s alpha of 0.93 and equivalent to that previously de-
scribed of 0.91.54 
 Symptoms of depression: were evaluated using the 9-item 
Patient Health Questionnaire (PHQ-9).55 Patients are asked to rate 
items according to how often symptoms have bothered them in 
the last 2 weeks on a 4-point Likert scale: 0 (not at all), 1 (several 
days), 2 (more than half of the days), and 3 (nearly every day). The 
total score ranges from 0 to 27, with a higher score indicating more 
depressive symptoms. The internal consistency was good with 
Cronbach’s alpha of 0.83 equivalent to that previously described of 
0.86-0.89.55 
 Symptoms of anxiety (Riata cohort only): were evaluated using 
the 7-item Generalized Anxiety Disorder questionnaire (GAD-7).55 
All items are rated as described above for the PHQ-9. The total 
score ranges from 0 to 21, with a higher score indicating more 
symptoms of anxiety. The internal consistency was excellent with 
Cronbach’s alpha of 0.91 in accordance with a previously described 
value of 0.92.55 
 The distressed (Type D) personality: was measured with the 14-
item Type D Scale.56 Type D personality is defined as a high score 
on negative affectivity (7 items, e.g. “I often feel unhappy”) and 
social inhibition (7 items; e.g. “I am a closed kind of person”). All 
items are rated on a 5-point Likert scale from 0 (false) to 4 (true). 
The total score for each subscale ranges from 0 to 28. Only patients 
scoring ≥ 10 on both subscales have a Type D personality. The 
internal consistency was good for both subscales with Cronbach’s 
alpha 0.93 and 0.85 in accordance with that previously described 
of 0.88 and 0.86, respectively.56  
 Impact on general well-being (Riata cohort only): was evaluated 
using a purpose-designed question: “What is the impact of the 
information about possible problems with your ICD lead on your 
general well-being”. This was answered using a visual analog scale 
(VAS) with a vertical 20 cm line from zero (marked no impact) to 10 
(marked most thinkable impact). The line had major ticks at inte-
gers and minor ticks at decimals. A high impact was defined a priori 
as VAS >5.  
 
Statistical considerations 
The analyses for the three studies were performed with Stata 
versions 11.2 and 13.1 (StataCorp, College Station, TX, USA). Two-
sided p-value <0.05 was considered statistically significant. All 
confidence intervals (CIs) were calculated with 95% limits. The 
choice of statistical tests including regression models depended on 
the distribution of the outcome variable and whether data were 
paired or unpaired.  
 Multivariable regression analyses were performed according to 
the commonly accepted rule of 10 events (binary outcome) or 20 
patients (continuous outcome) for each model parameter to en-
sure an appropriate model complexity.57 Covariates were selected 
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from predefined prioritized lists of potential confounders and 
predictors based on the literature and discussions with fellow 
researchers to reduce the risk of type 1 errors with rejection of 
false null hypotheses due to multiple testing. Bonferroni correction 
for multiple testing was not applied. This methodology is too con-
servative with a very high risk of type 2 errors with acceptance of 
false null hypotheses missing important associations, as it wrongly 
assumes the most likely reason for low p-values to be chance 
rather than the alternative hypothesis of a true association be-
tween tested groups.58 This is not the case if hypotheses are prede-
fined and theoretically sound. 
 No power calculations were performed as this would not have 
had any impact on the execution of the three descriptive observa-
tional studies with the maximum number of participants given 
beforehand, limited by the size of the Riata survivor cohort in 
Denmark. Therefore, the interpretation of neutral findings was 
done with caution and guided by a combination of the point esti-
mates and especially the width of CIs. A very wide CI indicates a 
reduced statistical power for a given analysis with an increased risk 
of type 2 errors.  
 Study I: The prevalence of ECs was calculated with CI. The asso-
ciation between lead dwell time and degree of externalization was 
analyzed by Spearman’s correlation. The fluoroscopic diagnostic 
performance was evaluated by calculation of Cohen’s Kappa, sensi-
tivity, specificity, and positive and negative predictive values, with 
the adjudicated findings as gold standard. Changes in electrical 
measurements from implant to fluoroscopic screening were ana-
lyzed using paired t-tests and adjusted for lead dwell time at base-
line screening using multivariable linear regression. Potential pre-
dictors of ECs were analyzed in a multivariable additive hazards 
regression assuming the data on ECs to be extremely interval cen-
sored between time of implant and fluoroscopic screening, also 
known as current status data.59 This was necessary as the silent 
nature of most ECs makes the exact time of development of a 
visible EC unknown. Due to few events only two potential predic-
tors were included: lead diameter and number of shock coils.  
 Study II: The incidence rate of ECs was calculated with CI using 
time-at-risk from baseline to latest fluoroscopy in patients with 
normal baseline fluoroscopy. Comparative analyses for incident 
ECs were made only by estimating crude incidence rate ratios due 
to low event count. The incidence rate of electrical abnormalities 
was calculated using time-at-risk from baseline to lead discontinua-
tion, death, or the second screening in patients with no baseline 
electrical abnormalities. Comparative analyses for electrical ab-
normalities were made by estimating crude incidence rate ratios 
and a simple adjusted multivariable analysis by Poisson regression 
with EC and lead diameter as covariates. 
 Study III: Baseline data in matched groups and within-patients 
over time were analyzed using logistic and linear regressions for 
paired data. Baseline data within the Riata cohort were analyzed 
using logistic and linear regressions for unpaired data. Covariates 
for the adjusted analyses between Riata patients and controls 
were: age, ischemic heart disease, cardiac resynchronization ther-
apy, self-reported other chronic diseases, shock therapy within one 
year (appropriate and inappropriate), high school, higher educa-
tion, Type D personality and ICD center. Covariates for analysis of 
independent predictors of a high impact of the advisory notifica-
tion were: age, female sex, ECs, and Type D personality. Covariates 
for the adjusted analyses of changes over time were new events 
since baseline screening believed to be of importance for changes 
in PROs: shock therapy, loss of spouse/partner, and new self-
reported chronic disease. Cohen’s effect size index d was used to 
determine the clinical relevance of estimated adjusted mean dif-
ferences (0.20 = small, 0.50 = moderate, ≥0.80 = large).60 Missing 
values were imputed using multiple imputation for covariates to be 
used in the adjusted regression analyses and for single items in 
multi-item questionnaires with acceptable data quality with >70% 
of items reported. Questionnaires with <70% items reported were 
excluded from analyses for that given PRO. Imputed missing values 
accounted for ≤ 2.5% for each covariate and also ≤ 2.5% of items 
for each questionnaire.
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 Results 
Detailed descriptions of the results are given in each paper. Here 
are the main results. 
 
Study I 
Study population 
All 299 living patients with recalled Riata leads attended the base-
line screening, but one patient did not undergo fluoroscopy due to 
severe disability and was excluded from data analyses. No signifi-
cant differences were seen in characteristics at time of lead im-
plant between patients with and those without ECs (Table 1). 
 
Table 1 Characteristics of patients and ICD systems in the 
Riata survivor cohort 
 EC 
(n = 32) 
No EC 
(n = 266) 
p- 
value 
Time of Riata implant    
  Age, years  61.3±12.5 62.6±11.8 0.56 
  Sex, men 78% 82% 0.60 
  Primary prophylaxis 13% [2] 26% [17] 0.18 
  IHD 63% [8] 71% [19] 0.39 
  LVEF, % 29±16 [18] 33±14 [96] 0.39 
Time of screening    
  Age, years 66.9±12.6 67.7±12.0 0.73 
  Height, cm 174±9 [3] 175±9 [14] 0.72 
  Weight, kg 82±17 [2] 83±18 [16]  0.68 
  Pacing dependence 9% 5% 0.21 
  Appropriate shock therapy 28% 26% 0.83 
  Inappropriate shock therapy 0% 9% 0.15 
  Total lead count 2 (1;3) 1 (1;3) 0.25 
  Lead dwell time (Riata), years 5.6±1.0 5.1±1.1 0.01 
  Lead diameter 8-F (Riata) 66% 29% <0.001 
  Single coil (Riata) 59% 47% 0.17 
  Septal position (Riata) 19%  24% [2] 0.52 
  Generator dwell time, years 4.8 (0.7;6.8) 4.5 (1.1;6.2) 0.65 
  Biventricular (generator) 34% 26% 0.31 
  Non-left pectoral (generator) 20% 11% 0.26 
Data are presented as mean ± SD, median (10th percentile; 90th percentile), 
and percentage. Missing values are reported in squared brackets. EC = 
externalized conductor; F = French; ICD = implantable cardioverter defibril-
lator; IHD = ischemic heart disease; LVEF = left ventricular ejection fraction.  
 
Baseline fluoroscopy 
The prevalence of ECs was 11% CI (7%; 15%) at a mean lead dwell 
time of 5.1 ± 1.1 years (Table 2). ECs were more common in 8-F 
than 7-F leads (21% vs. 6%, p < 0.001), but the 8-F leads also had a 
longer dwell time than 7-F leads (6.4 ± 0.8 vs. 4.5 ± 0.6 years, p < 
0.001).  
 The degree of externalization was significantly correlated to 
lead dwell time (Figure 7). All but one ECs were localized in the 
distal and intermediate intracardiac zones. ECs more often includ-
ed the distal zone 1 below the tricuspid valve annulus in dual coil 
leads than in single coil leads (69% vs. 16%; p = 0.004). No differ-
ence in location was seen between 8-F and 7-F leads, p = 0.17. 
 The agreement between the fluoroscopic evaluation of ECs by 
the attending electrophysiologists and the adjudicated fluoroscopic 
findings was excellent with a Kappa value of 0.88 CI (0.79; 0.97). 
The clinical diagnostic properties were: sensitivity 90% CI (74%; 
98%), specificity 99% CI (96%; 100%), positive predictive value 88%  
CI (71%; 97%), and negative predictive value 99% CI (97%; 100%). 
No single projection was 100% sensitive for the detection of ECs.  
 Lead diameter and number of shock coils were not independent 
predictors of the hazard of ECs in interval-censored time-to-event 
analysis, with an adjusted additive hazard for 8-F vs. 7-F = 2% CI (-
8%; 11%), and for single vs. dual coil = 0.1% CI (-4.7%; 4.9%). 
 
Table 2 Prevalence of ECs in 13 recalled Riata lead models 
Lead model Shock 
coils 
N Dwell time 
Years 
EC 
(95% CI) 
8-F Riata   98 6.4±0.8 21% (14%; 31%) 
  1570 Dual 11 6.3±0.6 27% 
  1572 Single 12 7.0±1.1 16% 
  1580 Dual 25 6.1±0.7 16% 
  1581 Dual 1 8.1 0%  
  1582 Single 43 6.3±0.6 28% 
  1590* Dual 1 6.9 0%  
  1591* Dual 3 6.8±0.0 0%  
  1592 Single 2 6.8±0.1 0%  
7-F Riata ST   200 4.5±0.6 6% (3%; 10%) 
  7000 Dual 74 4.5±0.6 5% 
  7001 Dual 38 4.1±0.5 5% 
  7002* Single 77 4.7±0.5 4% 
  7040 Dual 2 4.7±0.3 0%  
  7042 Single 9 4.6±0.2 22% 
All leads  298 5.1±1.1 11% (7%; 15%) 
Data are presented as mean ± SD and percentage with 95% confidence 
interval if appropriate. *Three integrated bipolar lead models with a pair of 
inactive filler cables to keep design balanced. CI = confidence interval; EC = 
externalized conductor; F = French; N = number of implanted leads. 
 
Electrical measurements  
The prevalence of electrical abnormalities was 6% in both patients 
with and those without ECs. Two patients with ECs had a supple-
mentary lead for pacing and sensing, but no new electrical abnor-
malities were observed. Three patients without ECs had supple-
mentary leads for pacing and sensing, and 14 patients had one or 
more new abnormalities at device interrogation in pacing thresh-
old (n = 1), R-wave sensing (n = 7), pacing impedance (n = 4), and 
non-physiological noise (n = 3). Figure 8 illustrates an example of 
post-shock noise in an electrogram from a patient with a Riata 
lead. High voltage lead impedance check was normal in all 117 
tested patients, and previous shock impedance was normal in all 
88 patients with a history of shock therapy. The only significant 
electrical difference between patients with and those without ECs 
was the pacing impedance at implant (568±142 vs. 512±118 Ω, p = 
0.02).  
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Figure 7 
 
Dot plot demonstrating an association between the externalization de-
gree and lead dwell time (n = 34). (1) = localized abnormal conductor 
spacing without overt EC; (2) = EC <1 cm length; (3) = EC >1 cm length lim-
ited to one zone of location; and (4) = EC >1 cm length crossing adjacent 
zones of location. Spearman’s rho = 0.37, P = 0.03. EC = externalized con-
ductor. 
Figure 8 
Near-field electrogram from a patient with a dysfunctional Riata lead demonstrating non-physiological noise revealed seconds after an appropriate shock 
therapy. The fluoroscopy was without externalization, and device interrogation and electrical measurements were otherwise normal. 
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 Study II  
Study population 
Four Riata patients were not included in the follow-up study due to 
severe stroke, terminal illness, emigration, or refusal to participate. 
The remaining 295 patients constituted the follow-up study cohort. 
At baseline in 2012, the thirty-four patients with ECs (incl. two 
borderline ECs) had significantly higher lead dwell time since im-
plant (5.5±1.0 vs. 5.1±1.1, p = 0.02) and higher proportion of 8-F 
leads (61.8% vs. 29.1%, p < 0.001) compared with patients without 
ECs. At the time of the second screening in 2013, 25 patients were 
dead, 23 leads had been abandoned, 15 leads had been extracted, 
and 232 leads were still active. 
 
Fluoroscopic follow-up 
In 239 patients with normal baseline fluoroscopy and repeated 
fluoroscopy after 1.1 ± 0.2 years, 10 new cases of incident ECs (2 
borderline and 8 overt) were confirmed at adjudication resulting in 
an incidence rate of 3.7 CI (2.0-6.9) per 100 person-years (Table 3), 
with no significant differences for lead diameter (p = 0.89), number 
of shock coils (p = 0.33), or dwell time since implant (p = 0.76).  
 The new ECs were detected in the intracardiac distal (n = 2) and 
intermediate (n = 8) zones with no differences between single and 
dual coil leads (p = 1.00). The eight overt ECs had a mean length of 
11 ± 3 mm (total range 5-14 mm). Valid measurement of EC length 
was not possible at follow-up in seven patients with baseline ECs, 
but the mean length of ECs in the remaining 27 patients with ECs at 
baseline increased by 4 ± 1 mm (P < 0.001) during a mean follow-
up of 1.1 ± 0.3 years (Figure 9). An example of changes over time 
with development of a new EC from baseline to follow-up is de-
picted in Figure 10.  
 
Table 3 Incidence of ECs in 13 recalled Riata lead models 
 Lead model N Risk 
time 
Years 
Incident  
cases 
Incidence rate  
per 100 PY  
(95% CI) 
8-F Riata 67 1.1±0.2 3 4.0 (1.3-12.3) 
  1570 7 1.2±0.2 0 - 
  1572 9 1.0±0.4 0 - 
  1580 18 1.1±0.1 1 - 
  1581 1 1.2 1 - 
  1582 27 1.1±0.2 1 - 
  1590* 1 1.1 0 - 
  1591* 3 1.2±0.3 0 - 
  1592 1 1.1 0 - 
7-F Riata ST  172 1.1±0.2 7 3.6 (1.7-7.5) 
  7000 64 1.2±0.3 3 - 
  7001 33 1.1±0.2 2 - 
  7002* 67 1.1±0.2 2 - 
  7040 1 1.0 0 - 
  7042 7 1.0±0.1 0 - 
All 239 1.1±0.2 10 3.7 (2.0-6.9) 
Risk time is presented as mean ± SD. The incidence rate ratio between 8-F 
vs. 7-F leads was 1.10 CI (0.28-4.24), p = 0.89. *Three integrated bipolar 
lead models with a pair of inactive filler cables to keep design balanced. CI = 
confidence interval; EC = externalized conductor; N = number of leads; PY = 
person-years. 
Figure 9 
 
Line and scatter plot illustrating the length outside the lead body of exter-
nalized conductors evaluated by fluoroscopy at baseline and follow-up (n = 
34). The mean length increased by 4 ± 1 mm during a mean follow-up of 1.1 
± 0.3 years. 
 
Figure 10 
 
Development of a new externalization in a patient with a single coil Riata 
lead from baseline to follow-up one year later. EC = externalized conductor. 
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Electrical follow-up  
In total, 20 incident electrical abnormalities were found (12 at lead 
discontinuations, 0 at death, and 8 at final interrogation) among 
276 patients with normal baseline electrical function followed for 
1.0 ± 0.3 years, resulting in an incidence rate of 7.1 CI (4.6; 11.0) 
per 100 person-years. This rate was higher with baseline EC, giving 
an incidence rate ratio of 4.4 CI (1.7; 11.5), p = 0.002, adjusted for 
differences in lead diameter (Table 4). Noise and impedance ab-
normalities were most common findings (Figure 11). 
 
Lead extraction outcomes 
Thirty-eight leads were discontinued with 15 extractions and 23 
abandonments. Reasons for discontinuation were electrical ab-
normality at baseline (n = 6), incident electrical abnormality during 
follow-up (n = 12), and prophylactic replacements (n = 20) of which 
12 were performed at elective generator replacement. Lead ex-
traction compared with lead abandonment was more frequent in 
younger patients (57.6 ± 14.5 vs 69 ± 7.5 years, p = 0.01). All leads 
were removed in toto with powered tools with one minor compli-
cation (a large pocket hematoma postponing discharge) and two 
major complications (a stroke due to paradoxical thromboembo-
lism, and a right ventricular wall tear with cardiac tamponade with 
successful thoracotomy but post-operative death nine days later 
due to respiratory failure). 
 
Prevalent findings in active leads at the 2013 
screening 
The prevalence of ECs in the 232 active leads was 11.2% CI (7.5-
16.0) at a lead dwell time of 6.2 ± 1.0 years. The prevalence of ECs 
was higher in 8-F leads (18.6% vs 8.0%, p = 0.02) with longer dwell 
time (7.5 ± 0.7 years vs 5.7 ± 0.6 years, p < 0.001). The prevalence 
of electrical abnormalities was 6.5% CI (3.7-10.4). Prevalent electri-
cal abnormalities were more common with prevalent ECs (19.2% vs 
4.9%, p = 0.02), mainly driven by a higher proportion of supple-
mentary pace-sense leads implanted in patients with ECs due to 
electrical abnormalities before the lead advisory. 
Figure 11  
 
Pie charts with incident electrical abnormalities during follow-up in patients 
with and those without baseline externalized conductors (n = 276). In case 
of several abnormalities in a patient, only the first on a prioritized list was 
depicted: lead noise, shock impedance abnormality, pacing impedance 
abnormality, poor R-wave sensing, and elevated pacing threshold. EC = 
externalized conductor. 
 
Table 4 Predictors of incident electrical abnormalities  
 Univariable  Multivariable 
 Yes 
IR/100 PY 
(95% CI) 
No  
IR/100 PY 
(95% CI) 
IRR 
(95% CI) 
p-value  Adjusted IRR 
(95% CI) 
p-value 
EC 27.4 (13.1-57.5) 5.1 (2.9-8.7) 5.4 (2.2-13.6) <0.001  4.4 (1.7-11.5) 0.002 
8-F lead  12.1 (6.7-21.8) 4.7 (2.5-9.1) 2.6 (1.1-6.2) 0.04  1.9 (0.8-4.8) 0.16 
Dwell time ≥ 6 years 9.9 (4.4-22.0) 6.3 (3.7-10.7) 1.6 (0.6-4.0) 0.36  - - 
Dual coil 8.5 (5.0-14.7) 5.4 (2.6-11.3) 1.6 (0.6-4.0) 0.33  - - 
Potential covariates for the multivariable analysis were pre-specified in a prioritized list, but due to few events, the association between externalized con-
ductors and electrical abnormalities was only adjusted for lead diameter. Lead dwell time from implant to baseline was strongly correlated with lead diame-
ter, spearman’s rho 0.79 (P < 0.001). EC = externalized conductor; IR= incidence rate; IRR = incidence rate ratio; PY = person-years. N = 276. 
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 Study III 
Study populations 
Riata patients were excluded from analyses if they had a previous 
class I lead advisory, no matched controls, no response to baseline 
questionnaires, or insufficient data quality (<70% reported items in 
all questionnaires). PROs were completed in 86% (256/299) of the 
patients at baseline and 70% (210/299) at follow-up. Most patients 
were screened within three months from identification in the 
Registry. Included Riata patients were not significantly different in 
terms of age, sex, ICD indication, and ischemic heart disease com-
pared with the non-included Riata patients, and follow-up re-
sponders were not significantly different from the surviving non-
responders in terms of age, sex, ICD indication, ischemic heart 
disease, and all baseline PROs. 
 At baseline, the included Riata patients were slightly older 
(67.8±10.9 vs 67.5±10.9 years, p = 0.04) despite age-group match-
ing, had an ICD implanted for a longer period of time (5.7±2.2 vs. 
1.0±0.1 years, p < 0.001), and were less likely to have Type D per-
sonality (9.3% vs. 18.2%, p < 0.001) as compared with the controls.  
 
Acute impact of the Riata advisory on PROs  
Baseline PROs are presented in Table 5. The mean scores for device 
acceptance (FPAS-12) were relatively high and for device-related 
concerns (ICDC-8) relatively low in both groups. However, Riata 
patients had significantly impaired crude and adjusted estimates 
for device acceptance and device-related concerns compared with 
non-advisory controls, although adjusted Cohen’s effect sizes were 
small. No differences were seen for depressive symptoms (PHQ-9). 
There were no significant differences in PROs between ICD centers. 
The 27 Riata patients with baseline ECs reported worse crude 
mean scores for all PROs except for depressive symptoms com-
pared with the 229 Riata patients with normal fluoroscopy, but 
none of these differences were statistically significant (Figure 12). 
 Female sex was the only significant univariable and multivaria-
ble predictor of a high impact of the advisory notification on gen-
eral well-being with an unadjusted odds ratio = 2.34 CI (1.12; 4.89) 
and adjusted odds ratio = 2.23 (1.05; 4.74), p = 0.04.  
 Our study design introduced a difference in time since first ICD 
implant with no group overlap, but a sensitivity analysis within the 
Riata cohort revealed no significant associations between time 
since implant and device acceptance (β = 0.05, p = 0.91), device-
related concerns (β = -0.25, p = 0.17), and depressive symptoms (β 
= 0.09, p = 0.49). 
 
Changes over time in PROs within the Riata cohort 
Changes in PROs from baseline to 1-year follow-up are presented 
in Table 6. Only very small significant improvements were seen in 
crude and adjusted mean device-related concerns. The estimated 
Cohen’s effect sizes for mean changes over time for other 
measures were close to zero. 
 Twenty-eight patients underwent lead replacement with only 
19 responders completing follow-up questionnaires. They were 
heterogeneous with 11 abandonments and 8 extractions, and 
reasons were 8 electrical failures and 11 prophylactic indications. 
At follow-up, patients who had underwent lead replacement re-
ported borderline significantly lower symptoms of anxiety (adjust-
ed GAD-7 change = -1.2, Cohen’s d = -0.26, p = 0.05). No significant 
differences were seen for the other PROs. 
 
 
Table 5 Baseline patient-reported outcomes in Riata patients versus matched controls 
 N Crude estimates  Adjusted estimates* 
Riata advisory 
(95% CI) 
Matched controls 
(95% CI) 
Difference 
(95% CI) 
 Difference 
(95% CI) 
Cohen’s d p-value 
Device acceptance 
(FPAS-12) 
498 74.9 (72.8; 77.1) 78.2 (76.1; 80.3) -3.3 (-6.2; -0.3)  -4.8 (-7.6; -2.0) -0.28 0.001 
Device-related concerns 
(ICDC-8) 
504 5.8 (5.0; 6.6) 4.5 (3.7; 5.3) 1.3 (0.2; 2.4)  2.0 (1.0; 3.0) 0.29 <0.001 
Depressive symptoms 
(PHQ-9)  
494 3.7 (3.1; 4.2) 3.7 (3.1; 4.2) 0.0 (-0.7; 0.8)  0.6 (-0.2; 1.3) 0.13 0.13 
Anxiety symptoms 
(GAD-7) 
248 1.8 (1.4; 2.3) - -  - - - 
Impact on well-being 
(VAS) 
245 2.7 (2.3; 3.0) - -  - - - 
Estimates are displayed as means with 95% confidence intervals. *The estimates are adjusted for age, ischemic heart disease, cardiac resynchronization 
therapy, self-reported other chronic diseases, shock therapy within one year (appropriate and inappropriate), high school, higher education, Type D person-
ality, and ICD center. CI = confidence interval; GAD-7 = Generalized Anxiety Disorder questionnaire; FPAS-12 = Florida Patient Acceptance Survey; ICDC-8 = 
ICD patient Concerns questionnaire; PHQ-9 = Patient Health Questionnaire; VAS = Visual Analog Scale (impact of lead advisory on general well-being).  
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Figure 12 
 
Bar chart representing crude mean-scores with error bars indicating 95% confidence intervals for the five patient-reported outcomes on patients’ well-being 
and psychological functioning. The left y-axis refers to Florida Patient Acceptance Survey (FPAS-12), and the right y-axis refers to ICD patient Concerns ques-
tionnaire (ICDC-8), Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder questionnaire (GAD-7), and impact on general well-being on a visual 
analog scale from 0 to 10 (VAS). 
 
Table 6 Changes in patient-reported outcomes in Riata patients after 1-year follow-up 
 N Crude estimates  Adjusted estimates* 
Baseline 
(95% CI) 
Follow-up 
(95% CI) 
Difference 
(95% CI) 
 Difference 
(95% CI) 
Cohen’s d p-value 
Device acceptance 
(FPAS-12) 
197 75.9 (73.6; 78.3) 75.3 (72.9; 77.6) -0.7 (-3.0; 1.6)  0.1 (-2.3; 2.6) 0.01 0.91 
Device-related concerns 
(ICDC-8) 
205 5.9 (5.0; 6.8) 5.2 (4.3; 6.1) -0.7 (-1.3; 0.0)  -1.1 (-1.8; -0.4) -0.17 0.002 
Depressive symptoms 
(PHQ-9)  
198 3.3 (2.7; 3.9) 3.6 (3.0; 4.2) 0.3 (-0.1; 0.7)  -0.05 (-0.5; 0.4) -0.01 0.83 
Anxiety symptoms 
(GAD-7) 
206 1.9 (1.4; 2.4) 2.0 (1.6; 2.5) 0.1 (-0.2; 0.5)  0.1 (-0.4; 0.5) 0.01 0.79 
Impact on well-being 
(VAS) 
196 2.6 (2.2; 3.1) 2.7 (2.3; 3.1) 0.1 (-0.3; 0.5)   -0.1 (-0.5; 0.4) -0.01 0.76 
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 Discussion 
In 2011, St. Jude Medical issued a class I advisory notification for 
the Riata defibrillator lead family due to an unexpected high rate of 
insulation failures including inside-out ECs seen by fluoroscopy.3 
Initially, not much was known about the failure mechanism of Riata 
leads. In the past 2½ years, the device-community has risen to the 
challenge with a high research activity, trying to uncover the natu-
ral history of these recalled troublesome leads. Much has been 
learned with contribution from the studies in this thesis, but many 
questions remain unanswered.  
 The main findings of the three studies were as follows: In the 
cross-sectional screening in Study I, the prevalence of ECs was 11% 
and significantly higher in 8-F compared with 7-F leads, but 8-F 
leads also had a significantly longer dwell time since implant, and 
no significant difference was seen in the hazard of ECs when ac-
counting for this time difference; the location of ECs was mainly 
intracardiac and differed significantly between single coil leads and 
dual coil leads; lead dwell time was significantly correlated to the 
degree of externalization; no association was observed between 
ECs and electrical abnormalities; and the fluoroscopic diagnostic 
performance for ECs was good. In the longitudinal follow-up in 
Study II, the nature of ECs was dynamic with development of new 
ECs and progression in size of existing ECs over time; the overall 
incidence rate of electrical abnormalities was high and 4.4-fold 
higher in leads with baseline ECs. In the cross-sectional comparison 
and longitudinal follow-up in Study III, patients in the Riata cohort 
reported a statistically significantly lower level of device ac-
ceptance (FPAS-12) and a higher level of device-related concerns 
(ICDC-8) as compared with matched non-advisory controls, alt-
hough the effect sizes were small; female sex was a significant 
independent predictor of an acute high impact of the advisory on 
general well-being; and there was only a minimal but significant 
reduction in device-related concerns over time. 
 
Prevalence, incidence rate, and risk of survivor 
bias 
The occurrence of a condition can be described using prevalence 
and incidence rate. The prevalence is a cross-sectional picture of 
the proportion of the condition at a specific point in time. It is 
therefore influenced by the incidence rate and duration of the 
condition.61  The prevalence of a condition in two groups can 
therefore be the same despite very different incidence rates and 
durations. In lead failure, patients with the most severe outcome 
would either die or have their lead changed before enrollment for 
a cross-sectional screening. Analyzing associations with lead failure 
using prevalence as outcome should therefore always be inter-
preted with extreme caution due to the risk of selection bias, in 
this case also called incidence-prevalence bias or survivor bias. 
Longitudinal prospective designs are not prone to this special kind 
of selection bias and are therefore always preferred in the analysis 
of associations of covariates with a given condition. This very im-
portant difference between prevalence and incidence should be 
kept in mind when interpreting differences in the findings of Study 
I and II. 
Prevalence, incidence, and dynamic nature of ECs 
(Study I & II) 
In 2008, the first case report with ECs was described by Duray et al 
in an 8-F lead with noise oversensing and inappropriate shock 
therapy.62 Several case reports followed with ECs detected by 
fluoroscopy due to concurrent electrical abnormalities.63-66 The 
first two retrospective lead performance studies without systemat-
ic fluoroscopy identified a prevalence of insulation damage of 0.2% 
(mean follow-up 18 months)67 and prevalence of ECs of 1.6% 
(mean follow-up 42 months),48 respectively. In December 2010, St. 
Jude Medical made their first “Dear Doctor letter” about the Riata 
leads.68 In this letter, they stressed that the 8-F and 7-F Riata sili-
cone leads were prone to outside-in abrasion failures, and about 
10% of reported insulation abrasions were unique inside-out with 
visible ECs. The company’s response to the observed insulation 
failures was that they stopped selling these leads with effect from 
31 December 2010, and they recommended follow-up according to 
standard best practice. The reason for not intensifying monitoring 
was that outside-in abrasions were mainly observed in the early 
life of the defibrillator leads within 27 months from implant, and 
about 90% of the leads in clinical practice had been implanted for 
more than 27 months. The data from the first prospective system-
atic fluoroscopic screening in Northern Ireland were presented by 
Kodoth et al at the European Society of Cardiology conference in 
fall 2011, showing an alarmingly high 15% prevalence of ECs with a 
mean dwell time of 48 months, and most leads had normal electri-
cal function despite the fluoroscopic lead status.43 In November 
2011, more than three years after the first case report, the class I 
Riata lead advisory notification was voluntarily issued by St. Jude 
Medical with a second “Dear Doctor letter”, in which they referred 
to the high 15% prevalence of ECs in the Northern Irish study but 
stressed that ECs were only seen in 0.1% of leads undergoing re-
turned product analysis.3 The low occurrence of ECs in the early 
studies without systematic fluoroscopic screenings is readily ex-
plained by short-term follow-up and by the electrically silent na-
ture of most ECs. The underreporting compared with the systemat-
ic fluoroscopic screening highlights the limitation of the insensitive 
current post-marketing surveillance mainly based on voluntary 
return product analysis and voluntary reporting to the FDA’s Man-
ufacturer and User Facility Device Experience (MAUDE) registry, 
which was also pointed out by Dr. Hauser in an editorial published 
shortly after the advisory notification.69    
 The largest multicenter study to date with systematic screening 
of 1029 Riata leads from the Netherlands reported a 14.3% EC 
prevalence at a median dwell time of 63 months.46 This is very 
close to the finding in Study I that provided an EC prevalence of 
11% with a median dwell time of 59 months (Table 2). In other 
prospective studies, the reported baseline EC prevalence varies 
from 11.5% to 27% in systematic fluoroscopic or x-ray screenings, 
generally with a higher prevalence in 8-F leads that also have a 
longer dwell time due to an earlier market introduction.70-78 Some 
of the differences between these cross-sectional studies may be 
explained by difference in study participation rate, lead dwell time, 
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use of supplementary leads in case of electrical abnormalities, 
implanting technique, included lead sub-models, and statistical 
uncertainty. The prevalence of ECs in the five largest multicenter 
studies including Study I was 11-22% and 21-33% for 7-F and 8-F 
leads, respectively.46, 70, 73, 75 The reason that our baseline preva-
lence of ECs was in the lower end of the reported range may be a 
high proportion of 7-F leads and the unselected properties of the 
nationwide cohort. The difference between 8-F leads and 7-F leads 
has been suggested to be explained by design improvements in 7-F 
leads by which the conductors are closer to the lead center and 
therefore less exposed to shear stress,75 but longer dwell time in 8-
F leads may also play an important part. For further discussion see 
section on predictors of ECs below.  
 The dynamics in the evolution of ECs are difficult to examine in 
cross-sectional designs, as most ECs are electrically silent, making 
the time of development of a visible EC extremely interval cen-
sored between implant and screening, typically more than 5 years 
later. The aforementioned cross-sectional studies with systematic 
screenings therefore cannot be used to determine whether an EC 
is a stationary or a dynamic finding beyond the first couple of years 
after implant. However, observations of higher EC prevalence46, 73, 
79 and larger EC size79 with increasing lead dwell time in these 
studies do render a dynamic nature of ECs probable as we ob-
served in Study I (Figure 7). The longitudinal data of Study II con-
firm this plausible dynamic progressive nature of ECs by showing 
that the size of existing ECs increased over time (Figure 9), and that 
new incident ECs developed despite long dwell time since implant 
with an incidence rate of 3.7 per 100 person-years (Table 3). The 
longitudinal data from the study with repeated fluoroscopy by 
Demirel et al demonstrated a higher incidence rate of 6.7 per 100 
person years,78 but this difference can readily be explained by 
statistical uncertainty. They also found a mean progression in the 
size of baseline ECs of 4 mm at their 1-year follow-up, similar to 
our findings.  
 
Location of ECs (Study I & II) 
In the advisory notification letter, the location of ECs was described 
to occur most commonly at the intracardiac level of the leads.3 This 
has been confirmed in several studies, including Study I and II. We 
found one EC at the level of the superior vena cava and the re-
maining in the intracardiac location. In Study I, we observed that 
ECs were significantly more common in the most distal part of dual 
coil compared with single coil leads. This was not a prespecified 
hypothesis, and the finding was not confirmed by the longitudinal 
data in Study II. However, this should be interpreted with caution 
due to few incident ECs with limited statistical power. A possible 
explanation for the observed difference between single and dual 
coil leads could be a stabilizing effect at the level of the superior 
vena cava or right atrium in dual coil leads of the proximal coil.  
 
Predictors of the development of ECs  
(Study I & II) 
Predictors of ECs have been examined in several studies. Suggested 
multivariable independent predictors using either logistic or Cox 
regressions are longer time since implant,72, 76 multiple leads,72, 77 
non-ischemic cardiomyopathy,77, 78 8-F lead diameter,76 female 
sex,78 lower left ventricular ejection fraction78, higher left ventricu-
lar ejection fraction,80 and decrease in R-wave sensing since im-
plant.80 However, these analyses have several limitations: (i) use of 
data-driven selection of variables for the multivariable analyses; (ii) 
they rely on cross-sectional data with prevalent ECs with inherent 
risk of survivor bias; (iii) they assume the time of development of 
ECs to be at the fluoroscopic screening despite the true extreme 
interval censored nature between implant and screening; and (iv) 
some, but not all, studies used unstable multivariable models with 
too many covariates included, resulting in unreliable estimates 
with extremely wide CIs. The use of data-driven variable selection 
may be a key explanation to differences in identified independent 
predictors between studies as chance rather than theoretical plau-
sibility drives the selection of covariates. The limitation of data-
driven variable selection is clearly demonstrated by its tendency to 
identify significant predictors even in completely random comput-
er-generated data.57  
 In Study I, we tried to address some of these challenges by an 
explorative analysis including only the two first potential predictors 
on a prespecified prioritized list using an interval censored additive 
hazard regression. This showed that neither lead diameter nor 
number of shock coils were significant predictors of ECs, but with 
very wide confidence intervals for the estimated additive hazards. 
This indicated that the present data set did not hold sufficient 
information to answer the tested null hypothesis with acceptable 
certainty due to a combination of extreme interval censoring, few 
events and only a small overlap in the ranges of dwell times since 
implant between 8-F and 7-F leads. Another approach to deal with 
the extreme interval censoring is simple stratification on lead dwell 
time as done in the Multicenter Riata Lead Evaluation Study, initi-
ated by St. Jude Medical, by Hayes et al including 776 patients with 
almost five times as many events as in our Study I.75 They demon-
strated a relatively strong univariable association between 8-F and 
ECs in the lower stratum with dwell time ≤6 years, and the groups 
did not differ significantly on other non-specified covariates. In 
Study II, 8-F was not a significant univariable predictor of incident 
ECs, but this neutral finding should be interpreted with caution due 
to low event count with limited statistical power. Thus, the associ-
ation between 8-F and ECs still remains to be confirmed in a pro-
spective longitudinal follow-up, but this may be very difficult as the 
mere suspicion that 8-F lead design may be a risk factor for ECs 
may result in selection bias due to differential loss to follow-up as a 
result of prophylactic lead replacement. A more active attitude 
toward lead replacement may also radically reduce the number of 
leads with new incident ECs as uncertain borderline subtle visible 
fluoroscopic abnormalities may result in replacement before true 
ECs develop. Given the current evidence, considering 8-F per se as 
high risk leads to guide follow-up and lead management, as sug-
gested in the 2012 German guidelines for Riata lead management, 
may be inappropriate. 81  
 
Electrical abnormalities and association with ECs 
in cross-sectional and longitudinal studies  
(Study I & II) 
The defibrillator lead is the weakest link in the ICD system, and 
insulation defects are the most common reason for failure.21 The 
definition of lead failure is used with little consensus in the general 
literature on defibrillator lead performance, which makes compari-
sons between studies challenging.24 In studies on Riata lead electri-
cal performance, including Study I and II, the applied definitions of 
lead failure vary, but most include non-physiological noise, imped-
ance abnormalities, and high pacing threshold, and some also poor 
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 R-wave sensing. However, exact criteria for electrical abnormalities 
in the studies differ. This contributes to the overall between-study 
differences in reported prevalence and incidence rate. However, 
the reported relative differences between sub-groups, such as 
patients with and those without ECs, should be affected to a less 
extent by differences in criteria for electrical abnormalities as long 
as the same objective criteria apply to the tested subgroups within 
the studies. 
 The electrical performance of recalled Riata leads has been 
described in several longitudinal studies. Early studies with short 
mean lead dwell times of less than two years show relatively low 
incidence rates of electrical lead failure <0.5% per year.67, 82, 83 
More recent studies with longer dwell times of between 3 and 5 
years demonstrate higher electrical failure rates ranging from 0.5% 
to 2.7% per year.48-50, 84-91 In one study, an acceleration over time 
in lead failure rate was described and was predicted past 4 years to 
be 5.2% per year.90 This is very close to the overall incidence rate 
of electrical abnormalities of 7.1 per 100 person-years described in 
Study II, with only a weak trend for 8-F diameter being an inde-
pendent predictor (adjusted incidence rate ratio 1.9, p = 0.16). 
Several of the studies have found a higher failure rate in 8-F 
leads,48, 50, 87, 90, 91 whereas others show higher failure rate in 7-F 
leads,49, 78 and one is neutral88. Compared with well performing 
benchmark leads, the recalled Riata leads have higher electrical 
failure rates.49, 50, 84, 86, 89, 90 Compared with recalled Sprint Fidelis 
leads, the results are less clear: some demonstrate higher failure 
rates in Sprint Fidelis leads,49, 86 and others are neutral.50, 84, 88  
 The clinical impact of ECs on the electrical lead function is not 
straightforward as most leads with ECs appear to be electrically 
well functioning. Studies with return product analysis of selected 
electrically failed leads have demonstrated a causal failure mecha-
nism of ECs with erosion of the ethylene-tetrafluoroethylene insu-
lation outside the protective silicone body.90, 92 Erosion due to a 
similar inside-out movement of conductors can also occur beneath 
shock coils not visible by fluoroscopy, but insulation failure is also 
seen due to outside-in abrasion, especially in the low-cycle high-
stress milieu of the shoulder-near pocket area.92 The cross-
sectional design has been used in several studies to investigate the 
association between ECs and electrical abnormalities. This is, as 
mentioned, a weak design to detect valid associations with dynam-
ic events like incident electrical abnormalities, as patients with 
events tend to be treated for their problem and lost before en-
rollment (survivor bias). This was the reason for our cautious inter-
pretation of the observed neutral association between ECs and 
electrical abnormalities in the baseline screening in Study I. We 
considered the significant finding of an unexplained 56 Ω higher 
pacing impedance in patients with ECs at implant a possible ran-
dom finding (type 1 error) due to multiple testing. In retrospect, an 
alternative plausible explanation could be that leads with ECs have 
been implanted in a way that increases intracardiac shear stress on 
the conductor cables. This will also stress the lead-endocardial 
interphase, which is known to increase pacing impedance.93 Signif-
icant associations between prevalent ECs and electrical abnormali-
ties have been reported in other studies: a higher proportion of 
prevalent electrical abnormalities (10.9% vs 3.5%, p < 0.001);46 a 
larger decrease in R-wave amplitude from implant to screening;73, 
80 and marginally higher pacing thresholds.76 Several retrospective 
studies with selective fluoroscopies and x-rays have suggested a 
possible association between ECs and electrical function.79, 89, 90  
 The longitudinal prospective design in Study II is a more power-
ful tool to investigate the possible association between ECs and 
electrical abnormalities, as it is less prone to selection bias if only 
few patients are lost to follow-up. Our findings of a strong associa-
tion therefore support a potentially true connection between ECs 
and electrical abnormality, with an adjusted incidence rate ratio of 
4.4 (Table 4). However, the confidence interval was relatively wide, 
from 1.7 to 11.5. Furthermore, we do not have return product 
analysis from the leads with electrical abnormalities as most leads 
were not extracted, and we therefore cannot verify causality be-
tween ECs and the observed electrical abnormalities. Perhaps ECs 
may only be a marker for a potentially failing “stressed” lead in 
accordance with the above described higher pacing impedance at 
implant. The other longitudinal prospective study to investigate 
this association is the Multicenter Riata Lead Evaluation Study.75 
They report on their preliminary results with only 10 electrical 
failures in 776 patients within a mean follow-up of about 10 
months, with no significant difference between patients with and 
those without ECs (2.0% vs 1.1%, p = 0.4). Analysis of data that 
have more events from longer follow-up including information on 
reasons for loss to follow-up in this large cohort is awaited. Their 
reported overall cumulated incidence of electrical abnormalities 
was much lower than in Study II and the majority of longitudinal 
studies with shorter lead dwell times as mentioned above. A small 
longitudinal study with externalized Riata leads showed an inci-
dence rate of electrical abnormalities of 6.4 per 100 person-years, 
but this estimate is very uncertain as the study only included two 
events in 52 patients.94 Additional explanations for the higher rate 
in Study II may be the unselected nationwide cohort, few patients 
lost to follow-up, differences in the applied definitions of electrical 
abnormalities/failures, but also possible differences in lead sub-
models. In Study II, only three patients with ECs had a lead model 
with integrated bipolar sensing with a pair of passive filler cables, 
so the chance that the observed externalized cables were electri-
cally active was above 95%. In most other studies, including the 
Multicenter Riata Lead Evaluation Study, sub-models are not re-
ported, and we therefore do not know the exact chance of a visible 
EC to be electrically active.      
 The loss to follow-up or censoring in time-to-event analyses is 
extremely important when analyzing the association between ECs 
and electrical abnormalities. Knowledge on fluoroscopic status of 
the leads may result in bias toward the null hypothesis if differen-
tial lead replacements are performed more often in leads with ECs 
before subtle sub-clinical electrical abnormalities are classified as 
true abnormalities. In the longitudinal fluoroscopic study by Demi-
rel et al, 96% (25/26) with ECs and only 18% (26/144) without ECs 
had their leads replaced prophylactically within the first year of 
follow-up.78 Thus, they wisely refrained from making any longitu-
dinal time-to-event analysis on electrical abnormalities as this 
would certainly have been invalid. Only time will tell if the findings 
in Study II will be confirmed in other studies with a similar low loss 
to follow-up, low degree of censoring, and relatively low rate of 
differential prophylactical lead replacements. It is notoriously 
difficult to investigate the true natural history of a lead malfunc-
tion as soon as the advisory has been notified. This has recently 
been demonstrated by Liu et al for recalled Sprint Fidelis leads with 
a decrease in failure rate over time, with a plateauing of the elec-
trical event-free survival curves due to prophylactical replacement 
in the first years after the advisory notification.28  
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 The observed electrical abnormalities in Study II are typical for 
structural lead failure with non-physiological noise and impedance 
abnormalities dominating in numbers both for patients with and 
those without ECs (Figure 11). Similarly, non-physiological noise 
was described as the most common electrical abnormality seen in 
one of the largest studies with follow-up of Riata leads without 
known fluoroscopic status.49 However, looking through the Riata 
literature, it is striking that pace-sense abnormalities are much 
more common than high voltage abnormalities, as from a design 
point of view, the low-voltage and high-voltage conductors should 
carry a more even risk in case of insulation defects. The most obvi-
ous explanation is that we do not have the right monitoring tools 
to validly detect small, but important insulation failures in the high 
voltage circuits. The first presentation of high voltage lead failures 
can be fatal or near fatal due to short circuits as described in re-
ports from the MAUDE registry.92, 95 Several case reports have 
demonstrated that low-voltage testing of shock impedance can be 
completely normal despite insulation failures in Riata leads with 
and without ECs only detected by failed high voltage shocks due to 
short circuits.96-98 In Study I, one patient demonstrated electrical 
abnormality with non-physiological noise only in relation to a high 
voltage shock, with all other measurements normal at the follow-
ing interrogation (Figure 8). In Study I and II, no patients under-
went high voltage shock testing, and only about half the patients 
had a low-voltage test of shock impedance of limited value. Sys-
tematic high voltage testing in patients with Riata leads has been 
performed in one study, in collaboration with St. Jude Medical, 
presented only as an abstract at the Heart Rhythm Society Con-
gress in 2013.99 Out of 289 patients with 36 cases of ECs, only 115 
patients underwent high voltage max output testing, and one 
patient with ECs had a failed shock due to low shock impedance 
<10 Ω. However, the number of tested patients with ECs was not 
reported, so we do not know the prevalence of high voltage fail-
ures in patients with ECs from this study. Even a normal high volt-
age test may not be enough as a case with shock testing in a Riata 
patient demonstrated three successful shocks, but the fourth failed 
due to short circuit with low shock impedance.100 In Study II, we 
only found a detailed description of reasons for death in medical 
records for about half the patients, and no systematic postmortem 
device-interrogation had been performed. We can only speculate if 
a number of fatal electrical failures are hiding among these un-
knowns. An independent study with systematic, synchronized high 
voltage shock testing without induction of ventricular arrhythmias 
is warranted. This should include Riata leads with and without ECs, 
but also other lead models from other manufacturers as the 
knowledge on high voltage performance of defibrillator leads 
implanted for more than 5 years is sparse. To make such a study 
feasible, it could be performed in relation to elective generator 
replacement. 
 
Lead replacement in patients living under the 
Riata lead advisory (Study II) 
Two high-volume singlecenter studies have demonstrated high 
extraction success rates for recalled Riata leads with relatively 
short dwell times.101, 102 In one of these studies, no difference in 
complication rate was observed compared with extractions of the 
recalled Medtronic Sprint Fidelis leads (10.6% vs 5.5%),102 but this 
neutral finding is limited by a low statistical power. The possibly 
more difficult extractions in Riata leads may be explained by no 
coating of the shock coils in the older 8-F leads and the disintegra-
tion of the lead body with ECs that can be worsened by pulling 
forces during extraction with snowplowing at the tip of the extrac-
tion catheter. In high volume extraction centers, the recalled Sprint 
Fidelis leads have very good extraction outcomes with 100% suc-
cess and low risk of complications, probably because these leads 
are all with coated shock coils and without disintegration of the 
lead body.103 A recent multicenter study showed 1.4% major com-
plications in 295 patients with Riata lead extraction, and in patients 
with ECs, laser sheaths were employed significantly more often.104 
We do not know whether these relatively favorable results from 
high volume centers apply to smaller centers, and as ECs can make 
the procedure more complex, it may be wise to leave the extrac-
tion of these leads to experienced extractors. In Study II, the ob-
served one minor and two major complications in only fifteen 
leads could be due to chance but should be a used as a reminder 
that lead extraction is not without risk. One of these complications 
was a stroke with paradoxical thromboembolism through a persis-
tent oval foramen,105 which may be directly linked to ECs, as it is 
suspected to be a predilection site of thrombus formation.106 How-
ever, lead-related thrombi can be seen in all types of intravascular 
leads.107 If the hypothesis of ECs being thrombogenic should be 
substantiated, a systematic controlled study is needed with 
transesophageal or intracardiac echocardiography in Riata patients 
with and without ECs. This could be done in patients undergoing 
elective lead replacement.  
 The progressive nature of ECs with increasing size over time and 
a strong association with new electrical abnormalities in Study II 
emphasizes that lead replacement should be considered in high-
risk patients and patients with long life expectancy, especially if a 
golden moment of opportunity arises as in elective generator 
replacement due to battery depletion or system up-grade. This was 
the strategy employed in the Danish Riata cohort. In 2012, we 
made a Danish national guideline for the management of the Riata 
leads based on the data from our own and other studies (Appendix 
IV). The risk associated with lead extraction is not zero, and an 
individualized approach weighing risk and benefits should guide 
the decision, always in respect of the wishes of a thoroughly in-
formed patient.35 We have to remember the lesson learned from 
the Teletronics Accufix atrial lead advisory, in which the risk at lead 
extraction was higher than the risk posed by the recalled lead 
failure itself.108 However, since then, extraction tools and experi-
ence have vastly improved. The American Heart Rhythm Society 
and the European Heart Rhythm Association have published posi-
tion papers on transveneous lead extraction emphasizing the need 
for well-equipped and well-trained high-volume lead extraction 
teams with immediate access to thoracic surgeon assistance to 
avoid unnecessary risks for the patients.35, 109   
 
ECs in non-recalled leads - new “icebergs” on the 
move?  
The design of the recalled 8-F and 7-F Riata leads has been im-
proved in its two St. Jude Medical successors, the 7-F Riata ST 
Optim and the 7-F Durata leads, most importantly by adding a 
resilient extra outer jacket of Optim, a copolymer of silicone and 
polyurethane 50 times stronger than silicone. Only a single case of 
EC has been reported in a Riata Optim lead just above the proximal 
coil where the lead, in contrast to the Durata design, is not covered 
by Optim insulation.110 No ECs have been detected in systematic111 
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 or selective112 screenings of the Optim coated leads. The design 
improvements with Optim will theoretically reduce the risk and 
rate of development of ECs, which is also supported by bench 
testing, demonstrating that differential pulling in the lead compo-
nents will be reduced due to the increased stiffness of the outer 
Optim co-polymer.45 As most ICD patients have relatively restricted 
expected life times, ECs therefore are less likely to become a clini-
cal issue for these leads. However, Riata ST Optim and Durata leads 
are not protected by inside-out movement beneath the shock coils, 
so electrical failure due to erosion of the inner ethylene-
tetrafluoroethylene coating of the conductors can develop and 
may become a clinical problem with time. Several reports on this 
have already been registered in the MAUDE registry or presented 
in case reports.113, 114 However, the early reports on the electrical 
performance of Durata leads seem to be favorable,91, 111, 112 but 
these are limited by the fact that fatal high voltage shock failure 
due to short circuits will most likely not be detected. This has 
raised concerns in the device community about the true long-term 
performance of these leads and about the lack of sensitive tools to 
monitor and identify patients at risk just as for the Riata pa-
tients.100 Currently, the brand new successor to the Durata lead 
has just been launched to the market (Optisure) with an increased 
thickness of the outer Optim jacket with increased recommended 
introducer size from 7-F to 8-F and also Optim insulation beneath 
the shock coils to avoid internal short circuits. It seems as if the 
manufacturers’ race to make constantly smaller diameter leads has 
been halted…at least temporarily. In the spring of 2014, there have 
also been reports of findings of ECs in defibrillator leads from 
Biotronik,115, 116 but at the current time we have no scope of the 
size of this only potential problem. 
 
The patient perspective on the Riata lead 
advisory (Study III) 
Physicians may be challenged by the Riata advisory, but what 
about patients? What is the impact of the Riata advisory notifica-
tion on their well-being and psychological functioning? The FDA 
does not recommend routine replacement of Riata leads with 
normal electrical function.117 Many patients therefore live with an 
active Riata lead under advisory with a potential negative influence 
on their health-related quality of life. To our knowledge, Study III is 
the first in the world to have addressed this. 
 The elusive complex Riata failure mechanism with no reliable 
means for monitoring may contribute to the observed negative 
impact on device acceptance and device-related concerns in the 
early advisory phase as presented in Table 5 and Figure 12. The 
ICDC-8 is mainly measuring device-related concerns for shock 
therapy, and our data therefore suggest that the advisory notifica-
tion may induce acute anticipatory shock anxiety with some im-
provement over time, possibly due to adaptation, despite no in-
formation delivered to patients on increased risk for inappropriate 
shock therapy. A maintained loss of confidence and negative atti-
tude toward ICD technology may be a key explanation for the 
observed preserved reduction in device acceptance.118 Neverthe-
less, despite a statistically significant impact, effect sizes were 
small questioning whether the impact on patients’ health-related 
quality of life can be considered clinically relevant. The observed 
small effect sizes might be due to no media exposure in the early 
advisory phase in Denmark, where all patients learned about the 
advisory from their physician.119 Patients with ECs might be partic-
ularly vulnerable, as we observed the lowest mean score for device 
acceptance and the highest mean scores for device-related con-
cerns, symptoms of anxiety, and impact on general well-being in 
this subset of patients, although this was not statistically signifi-
cant, possibly due to our limited sample size (Figure 12). The bor-
derline significant small improvement in symptoms of anxiety in 
Riata patients undergoing lead replacement seems plausible but 
should be interpreted with caution as this was not a pre-specified 
hypothesis. 
 Previous studies on the patient perspective on advisory notifi-
cations are conflicting. The Sprint Fidelis advisory is the one most 
comparable with the Riata lead advisory, but the failure mecha-
nism in Sprint Fidelis leads is more transparent and mainly includes 
low-voltage failures due to conductor fracture, and in contrast to 
the Riata leads, impeding lead failure can be monitored successful-
ly, reducing but not eliminating the risk of inappropriate shocks.120 
Conform to our findings, Heatherly et al observed a significantly 
higher level of device-related concerns in 158 Sprint Fidelis pa-
tients compared with non-advisory controls with the majority 
examined within 18 months from the advisory notification.30  Two 
earlier smaller follow-up studies also indicate a higher level of 
general anxiety after generator advisory notifications.121, 122 Con-
flicting with our findings, the studies by Keren et al (n = 273 adviso-
ry patients), Pedersen et al (n = 207 advisory patients), and 
D’Antono et al (n = 114 advisory patients) did not find any signifi-
cant impairment in the psychological functioning of Sprint Fidelis 
advisory patients compared with non-advisory controls.31-33 These 
three studies were not performed in the early advisory phase, but 
after 9-24 months. The timing for assessment of the impact of the 
device advisory may be a key factor in explaining the inconsistent 
results so far, which is in line with our observed minimal, but signif-
icant reduction in device-related concerns over time (Table 6). The 
neutral findings by Keren et al may also be explained by a very 
well-established advisory management program inviting patients 
and relatives in for a 1-hour lecture and individual discussions with 
their physician.31 
 Female sex was an independent predictor of an acute high 
impact on general well-being in Study III. In a small follow-up 
study, an analog higher “worry-score” was seen in women in the 
early generator advisory phase.123 Selected studies examining 
gender disparities in ICD patients have also reported higher levels 
of psychological distress in women,124 but sufficiently powered 
studies designed a priori to evaluate gender differences on PROs 
are warranted to determine whether women truly comprise a 
more vulnerable group than men.125  
 The results of Study III suggest that Riata advisory patients have 
a significant impairment in general well-being and psychological 
functioning even in a setting without early media exposure. The 
awareness of possible negative psychological consequences of 
advisories is important to provide the best patient-centered care. 
Patients should be provided with access to health care profession-
als with expertise in device management, education and counsel-
ing to ensure awareness and anxiety are addressed in the context 
of an advisory. The inclusion of PROs in national registries with 
repeated assessments as part of standard practice would enhance 
our knowledge of the impact of device advisories on patients. 
Generally, larger studies have to be set up after advisory notifica-
tions are released, which is currently occurring ad hoc and in most 
cases a long time after the notifications have been released. This is 
not optimal from a design point-of-view, and is unlikely to provide 
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the knowledge needed to improve the care of patients with hard-
ware under advisories. 
 
Limitations  
The three studies in this thesis have differences in designs, but all 
are observational, based on a survivor cohort with data from sev-
eral sources, including the Danish ICD Register, clinical outpatient 
visits with fluoroscopy and device interrogation, and question-
naires completed by patients. Hence, results can be subject to 
selection bias and information bias, and tested associations be-
tween sub-groups can be subject to confounding due to lack of 
randomization.  
 Selection bias is an error in estimates due to systematic differ-
ences in characteristics between those selected for a given analysis 
and those not selected.61 In the prospective cross-sectional Study I, 
estimating the occurrence of ECs and electrical abnormalities using 
prevalence can underestimate the true problem due to a kind of 
selection bias called survivor bias as described above. However, 
the cross-sectional design is most often the only possibility in an 
early phase of describing an acute clinical problem to give some 
sort of estimate of the size of problem, but it should always be 
interpreted with caution. Study I included a near to complete 
nationwide cohort leaving no risk for further selection bias, result-
ing in a valid point-in-time picture. In the prospective longitudinal 
Study II, the risk of selection bias was quite small as we only lost 
three patients to overall follow-up, but further 25 patients died 
before follow-up fluoroscopy, and if these patients differed sub-
stantially from the survivors in risk of developing ECs, a small bias 
cannot be excluded. In Study III, the risk of selection bias in the 
Riata cohort was small due to high baseline study participation, 
low loss to follow-up, and no significant difference in characteris-
tics between responders and non-responders at baseline and 
follow-up. The matched non-advisory controls were selected by 
random from a large nationwide cohort of consecutive patients 
who survived and responded to questionnaires one year after first-
time ICD implant. The matching was on age group, sex, and ICD 
indication, and potential selection bias cannot be ruled out in these 
patients as demonstrated by a higher proportion of type D person-
ality compared with the Riata cohort, but this was controlled for in 
analyses by supplementary use of multivariable regression. 
Comorbidity was adjusted for by proxy variables such as age and 
ICD indication but not functional status. However, the applied 
adjustments enlarged estimated differences (suppressor effect), 
which indicates slightly more comorbidity in the controls. Residual 
confounding is therefore less likely as an explanation for the im-
paired baseline PROs in the Riata cohort. Time since first ICD im-
plant was different by design in the Riata cohort and non-advisory 
controls with no group overlap, which could therefore not be 
controlled for statistically. But within the Riata cohort, no signs 
were seen of a worsening in PROs over time, and the estimates for 
the primary endpoints pointed in the opposite direction. It is there-
fore less likely that the differences we observed in PROs between 
Riata patients and controls could be explained by time-related 
confounding. This is also in line with the fact that PROs tapping into 
psychological functioning are relatively stable beyond 3-6 months 
after implant.126 The use of multiple imputation in case of missing 
values also contributed to less risk for selection bias as the alterna-
tive would have been excluding patients with non-complete ques-
tionnaires or using more primitive imputation methods, such as 
simple mean imputation, that tend to inflate the statistical power 
of the collected data.    
 Information bias is an error in estimates due to systematic 
inaccuracy of measurement/classification of exposures, covariates, 
and outcomes.61 Data on hardware and clinical variable registered 
in the Danish ICD Register were validated in a random sample of 
200 patients with high positive predictive values >90%, but we 
cannot with certainty rule out that a few patients in Denmark with 
Riata leads have not been identified due to misclassification. In 
Study I and II, the definition of ECs was adjudicated using multiple 
investigators, but the use of expert fluoroscopic consensus as gold 
standard may introduce minor misclassification of leads with small 
ECs in some areas with less lead movement and in the busy pocket 
area. A case report has demonstrated that fluoroscopy may be 
insensitive to small ECs when compared with findings from extrac-
tions,127 but extraction forces in this case report may just have 
accentuated a latent EC. Lead extraction followed by return prod-
uct analysis was not feasible in our nationwide observational stud-
ies. Electrical abnormalities were defined using absolute limits, 
relative changes over time, and expert panel evaluation blinded 
from fluoroscopic status, reducing the risk of misclassification. 
However, we cannot account for possible underestimation of high 
voltage abnormalities as reliable tools for this purpose are limited, 
and only about half the patients underwent high voltage integrity 
check. However, we tested the relative differences between 
groups of patients, and these associations should be valid assum-
ing no differential misclassification between groups. In Study III, we 
used standardized and validated multi-item questionnaires on 
PROs, reducing the risk of misclassification. A purpose-designed 
single-item VAS seemed appropriate to evaluate overall impact on 
general well-being as a single global quality of life VAS has previ-
ously been demonstrated to have good validity, reproducibility, 
and responsiveness over time.128  
 Estimated associations can be subject to confounding by a 
given variable if it (i) is a risk factor for the outcome, (ii) is associat-
ed to the exposure of interest, and (iii) is not part of the causal 
pathway between the exposure and outcome.129 We managed the 
risk of confounding in all three studies using multivariable regres-
sion analysis with prespecified potential risk factors for the out-
come as covariates, and in Study III we also used matching. How-
ever, the relatively small sample size and low number of events in 
the studies limited our possibilities of making rich regression mod-
els, increasing the risk of residual confounding. Furthermore, we 
can only adjust for known measurable confounders, and this is why 
associations tested in observational data should always be inter-
preted with caution, with only very careful claims of possible cau-
sality in case of strong associations in prospective longitudinal 
data.  
 The moderate sample size of the Riata cohort and relatively few 
events seen from a statistically point of view resulted in a relatively 
low statistical power for comparative analysis. Therefore, neutral 
findings should be considered tentative as the risk of type 2 errors 
with acceptance of false null hypotheses is generally elevated. 
Multiple testing for PROs in Study III without Bonferroni correction 
increased the risk of type 1 errors with rejection of true null hy-
pothesis, but this risk was acceptably reduced by interpretation of 
the findings in relation to prespecified prioritized hypotheses.
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 Main conclusions 
Study I  
The prevalence of ECs in a complete nationwide screening of active 
recalled Riata leads is at the same level as reported in previous 
studies with similar lead dwell times. The degree of externalization 
is time dependent, and location seems to differ between single and 
dual coil leads. Long-term lead performance and the association 
between ECs and electrical failure need further clarification. Fluor-
oscopy has a good diagnostic performance for ECs in clinical prac-
tice. 
 
Study II 
The development of ECs is a dynamic and progressive process 
despite long lead dwell time. ECs are associated with a higher risk 
of electrical abnormalities. Therefore, lead replacement should be 
considered, especially in patients with long life expectancy. 
 
Study III 
The Riata advisory is associated with a persistent small reduction in 
device acceptance and a small increase in device-related concerns 
with minimal improvement over time. Female sex is a predictor of 
a high negative advisory impact on general well-being. A need for 
counseling may arise in vulnerable subsets of patients. 
Overall conclusion of the thesis 
The prevalence of ECs in a complete nationwide screening of active 
recalled Riata leads is at the same level as reported in previous 
studies with similar lead dwell times. The development of ECs is a 
dynamic process with a relatively high incidence rate and progres-
sion in size over time. ECs are associated with a higher risk of inci-
dent electrical abnormalities. The current tools for monitoring 
insulation failures seem to be inadequate, and prophylactic Riata 
lead replacement should be considered on an individual level, 
especially in patients with long life expectancy. The Riata advisory 
is associated with a persistent small reduction in device acceptance 
and a small increase in device-related concerns with minimal im-
provement over time. Female sex is a predictor of a high negative 
advisory impact on general well-being. A need for counseling may 
arise in vulnerable subsets of patients.  
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Perspectives  
The studies in this thesis have contributed with results to increase 
our understanding of the complexity of the major Riata defibrilla-
tor lead class I advisory, seen from the perspective of both physi-
cians and patients. We have so far learned important lessons from 
this advisory. It has been highlighted that our current methods for 
monitoring the integrity of the high voltage circuits of ICD systems 
are not reliable. This has to be improved as high voltage failure is 
the ultimate most critical and often fatal failure of an ICD system, 
but it will often not be recognized in clinical practice outside the 
hospitals. This is, in my opinion, the most import single issue to be 
further explored in new studies on the Riata advisory. 
 It is striking that more than three years passed from publication 
of the first case report with ECs in 2008 until the advisory notifica-
tion was issued in 2011, and even at that time, the proportion of 
ECs, based on return product analysis, was only 1% of what was 
observed in later systematic fluoroscopic screenings. This empha-
sizes that the combination of a fast 510k-approval without clinical 
testing and poor demands for systematic post-marketing monitor-
ing of cardiac implantable electronic devices is a dangerous cock-
tail. Mandatory and independent hardware registries as the Danish 
Pacemaker and ICD Register can act as a role model for registries 
to enable a better monitoring, but to increase the sensitivity to 
timely detect potentially problematic devices and leads, we should 
strive to improve the international collaboration between regis-
tries. In retrospect, it would probably have been wise if two or 
three large and sufficiently powered studies, independent of the 
industry, were launched at the time of an advisory notification to 
answer the key questions important for lead management in the 
interest of patients, physicians, and industry. The many interested 
parties in the highly competitive device industry with high econom-
ical stakes make advisory notifications complex with intensified 
intricacy via media exposure. Declaring new “icebergs” every time 
we see a small drift of snow should therefore be avoided. The 
losers are the patients. Generally, physicians and industry should 
make every effort to collaborate as soon as technical hardware or 
software problems arise and work on the problems instead of 
making things worse by guessing. This has been the applied model 
for good collaboration between implanting hospitals and industry 
for years in Denmark including the management of the Riata advi-
sory. History has shown that advisory notifications are a natural 
part of rapidly evolving disruptive technologies, and we should 
continually learn from our mistakes and be even better prepared 
for the next advisory notification….it will come. This will get us 
closer to our common goal: to provide the best care for our pa-
tients. 
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 Summary 
Introduction: Implantable cardioverter defibrillator (ICD) therapy is 
well established for prophylaxis of sudden cardiac death. The 
weakest link of the ICD is the defibrillator lead connecting the 
pulse generator to the heart. In three studies, the present thesis 
describes the nature of the class I advisory concerning malfunction 
of the St. Jude Medical Riata defibrillator lead family, which was 
recalled in 2011 due to increased risk of insulation failures, includ-
ing fluoroscopically visible inside-out externalized conductors 
(ECs). The overall aim of the studies was to provide data to support 
an evidence-based clinical management of the patients living un-
der the Riata lead advisory.  
 Methods: In March 2012, a Danish nationwide cohort of 298 
patients with active recalled Riata leads was established. In Study I, 
a cross-sectional screening was performed with fluoroscopy in 
three projections and device interrogation at five ICD implanting 
hospitals. In Study II, the patients were followed for 1 year until a 
similar final second screening. In Study III, the patients’ perspective 
on the advisory was examined using patient-reported outcomes 
(PROs) measured by standardized and validated questionnaires 
tapping into their well-being and psychological functioning. The 
PROs were evaluated at the baseline and follow-up screenings for 
the Riata patients. Baseline PROs in Riata patients were compared 
with matched non-advisory controls. Clinical relevance of mean 
adjusted differences in PROs was evaluated using Cohen’s effect 
size d (0.20 = small; 0.50 = moderate; ≥0.80 = large).  
 Main results: In Study I, the prevalence of ECs was 11% and 
significantly higher in 8-F (21%) compared with 7-F (6%) leads, but 
8-F leads also had a longer dwell time since implant; the location of 
ECs was mainly intracardiac and more often included the lead 
segment below the tricuspid annulus in dual coil leads as com-
pared with single coil leads; lead dwell time was significantly corre-
lated to the degree of externalization; no association was observed 
between ECs and electrical abnormalities; and the fluoroscopic 
diagnostic performance for ECs was good. In Study II, the nature of 
ECs was dynamic with development of new ECs with an incidence 
rate of 3.7 per 100 person-years and significant progression in size 
over time of 4 ± 1 mm of existing ECs; the overall rate of electrical 
abnormalities was 7.1 per 100 person-years with an adjusted inci-
dence rate ratio for patients with baseline ECs of 4.4 (p = 0.002). In 
Study III, there were a significant lower level of device acceptance 
(d = -0.28, p = 0.001) and a higher level of device-related concerns 
(d = 0.29, p < 0.001) in the Riata cohort as compared with non-
advisory controls, although the effect sizes were small; no signifi-
cant difference was seen for symptoms of depression; female sex 
was a significant independent predictor of an acute high impact of 
the advisory on general well-being; and there was only a minimal 
reduction in device-related concerns (d = -0.17, p=0.002) over time 
and no changes were seen in the other PROs.  
 Main conclusions of the thesis: The prevalence of ECs in a 
complete nationwide screening of active recalled Riata leads is at 
the same level as reported in previous studies with similar lead 
dwell times. The development of ECs is a dynamic process with a 
relatively high incidence rate and progression in size over time. ECs 
are associated with a higher risk of incident electrical abnormali-
ties. The current tools for monitoring insulation failures seem to be 
inadequate, and prophylactic Riata lead replacement should be 
considered on an individual level, especially in patients with long 
life expectancy. The Riata advisory is associated with a persistent 
small reduction in device acceptance and a small increase in de-
vice-related concerns with minimal improvement over time. Fe-
male sex is a predictor of a high negative advisory impact on gen-
eral well-being. A need for counseling may arise in vulnerable 
subsets of patients.  
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Dansk resumé 
Introduktion: En implanterbar cardioverter-defibrillator (ICD) er 
effektiv som profylakse mod pludselig hjertedød. Det svageste led i 
ICD-systemet er ledningen, der forbinder pulsgeneratoren med 
hjertet. Denne ph.d.-afhandling beskriver i tre studier forskellige 
aspekter af tilbagekaldelsen af Riata ICD-ledninger fra firmaet St. 
Jude Medical. Tilbagekaldelsen blev foretaget i 2011 på grund af 
uventet høj forekomst af isoleringsdefekter, inklusiv eksternalise-
ring (EC), hvor de elektriske kabler i ledningen bevæger sig uden 
for den beskyttende ydre silikoneisolering. Det overordnede formål 
med studierne var at indhente viden til at understøtte en evidens-
baseret klinisk håndtering af patienterne med tilbagekaldte Riata-
ledninger. 
 Metoder: I marts 2012 blev der identificeret en national dansk 
kohorte med 298 patienter med aktive Riata-elektroder. I studie I 
blev der udført en tværsnitsscreening med røntgengennemlysning 
af ledningen i tre projektioner og kontrol af ICD’ens elektriske 
funktion på fem ICD-implanterende hospitaler. I studie II blev 
patienter fulgt 1 år frem til en tilsvarende screening. I studie III 
blev patienternes perspektiv på tilbagekaldelsen af ledningerne 
undersøgt med validerede spørgeskemaer ved de to screeninger 
omhandlende indflydelse på det almene velbefindende og psyko-
logisk status. Resultater fra baseline-screeningen blev sammenlig-
net med resultater fra en matchet kontrolgruppe uden en tilbage-
kaldt ledning. Den kliniske relevans af justrede middelforskelle i 
resultater fra spørgeskemaerne blev vurderet med Cohen’s effekt-
størrelse d (0.20 = lille; 0.50 = moderat; ≥0.80 = stor).  
 Hovedresultater: I studie I var prævalensen af EC 11% og signi-
fikant højere ved 8-F (21%) sammenlignet med de lidt tyndere 7-F 
(6%) ledninger, men 8-F ledninger havde været implanteret i signi-
fikant længere tid; EC blev primært set intrakardielt og hyppigere 
distalt for tricuspidalklappen ved dobbelt coil ledninger; tid siden 
implantation var signifikant korreleret med graden af EC; Ingen 
association blev set mellem EC og elektriske abnormiteter; og de 
kliniske diagnostiske egenskaber af gennemlysninger for EC var 
gode. I studie II var EC dynamisk med udvikling af EC med incidens-
rate 3.7 per 100 personår og progression i størrelsen af eksisteren-
de EC over tid på 4 ± 1 mm; den overordnede incidensrate af elek-
triske abnormiteter var 7.1 per 100 personår, med en justeret 
incidensrateratio for patienter med baseline EC på 4.4 (p = 0.002). I 
studie III havde Riata-patienterne en signifikant dårligere accept af 
at leve med ICD’en (d = -0.28, p=0.001) og en højere grad af ICD-
relaterede bekymringer (d = 0.29, p<0.001) sammenlignet med 
kontrolgruppen, men effektstørrelserne var små; der var ingen 
forskel for symptomer på depression; kvindekøn var en signifikant 
uafhængig prædiktor for, at tilbagekaldelsen af ledningen havde en 
stor indflydelse på det almene velbefindende; og der var kun en 
mindre reduktion i ICD-relaterede bekymringer (d = -0.17, p=0.002) 
over tid, og ingen signifikante ændringer i de øvrige selvrapporte-
rede psykologiske mål. 
 Hovedkonklusioner: Prævalensen af EC i en komplet national 
screening af aktive, tilbagekaldte Riata-ledninger er på samme 
niveau som i sammenlignelige studier. Udviklingen af EC er en 
dynamisk proces med en relativ høj incidensrate og progression i 
størrelsen af eksisterende EC over tid. EC er associeret til en højere 
risiko for senere udvikling af elektriske abnormiteter. De aktuelle 
muligheder for at monitorere isoleringsfejl på højvoltsdelen af en 
ICD-ledning er begrænsede, og profylaktisk skift af tilbagekaldte 
Riata-ledninger bør overvejes, særligt hos patienter med forventet 
lang restlevetid. Tilbagekaldelsen af Riata-ledningerne har en akut 
effekt på patienternes almene velbefindende og psykologiske 
status med en vedvarende let nedsat accept af at leve med ICD’en 
og en let øgning i ICD-relaterede bekymringer, som kun forbedres 
minimalt over tid. Kvindekøn er prædiktor for en stor negativ tilba-
gekaldelseseffekt på det almene velbefindende. Behov for psyko-
loghjælp kan komme på tale hos skrøbelige patienter.  
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Danish Riata lead management plan (September 12, 2012) 
Concerning recalled St. Jude Medical Riata ICD 
leads 
• Model no. 1560, 1561, 1562, 1570, 1571, 1572, 1580, 
1581, 1582, 1590, 1591, 1592, 7000, 7001, 7002, 7010, 
7011, 7040, 7041, and 7042. 
Recommendations for all leads 
• Remote monitoring is recommended if possible. 
• Outpatient visits are recommended 4 times a year (at 
least once a year in case of remote monitoring). Routine 
test of high voltage impedance using painful low-voltage 
shock is not recommended. 
• Fluoroscopy is recommended every 12 months in active 
leads in an ICD implanting center. 
Patients with electrical abnormalities 
with/without externalization   
• Electrical abnormalities are typically rising impedance, 
falling R-wave sensing, rising pacing threshold and noise. 
Lead replacement is recommended with extraction or 
abandonment of recalled lead. 
Patients with externalization without electrical 
abnormalities 
• High risk: secondary preventive ICD indication, previous 
relevant ICD therapy, pacing dependence and responders 
to cardiac resynchronization therapy. Prophylactical lead 
replacement is recommended with extraction or aban-
donment of recalled lead. 
• Low risk: primary preventive ICD indication, no previous 
relevant ICD therapy, no pacing dependence and non-
responders to cardiac resynchronization therapy. It is 
recommended to consider prophylactical lead replace-
ment with extraction or abandonment of recalled lead. 
The choice is based on an individual evaluation including 
patients’ wishes and can, if necessary, wait until planned 
generator replacement. 
Patients without externalization or electrical 
abnormalities 
• Strategy at elective generator exchange will depend on 
an individual evaluation including patients’ wishes in re-
lation to possible lead replacement with extraction or 
abandonment of recalled lead. 
The experience with extraction of Riata leads is sparse. Externaliza-
tion of conductor cables may increase difficulty of the procedure, 
which is the tendency described in the first small international 
extraction reports. In general, extraction will be more difficult and 
with higher risk, the longer the leads have been implanted. We 
therefore recommend that extraction is considered in selected 
patients, especially younger patients, in regard to ICD indication, 
comorbidity, and type of device. 
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